

Farmasi Klinis dan Pengobatan Presisi



apt. Kurnia Eryani, S.Farm., M.Farm.Klin.
apt. Nur Rezky Rutami Amir, S.Farm., M.Farm.Klin.

Farmasi Klinis dan Pengobatan Presisi

apt. Kurnia Eryani, S.Farm., M.Farm.Klin.
apt. Nur Rezky Rutami Amir, S.Farm.,
M.Farm.Klin.



PT YAPINDO JAYA ABADI

Anggota IKAPI: No. 627/DKI/2023

Farmasi Klinis dan Pengobatan Presisi

Penulis : apt. Kurnia Eryani, S.Farm., M.Farm.Klin., dan
apt. Nur Rezky Rutami Amir, S.Farm., M.Farm.Klin.
ISBN : 978-634-7789-60-0 (PDF)
Penyunting Naskah : Fahrul Rozi
Tata Letak : Fahrul Rozi
Desain Sampul : Novikean Keysah Sanisri

Penerbit

PT Yapindo Jaya Abadi

Jl. Tanjung Duren Raya No. 89 C RT 06/RW 05, Kelurahan Tanjung Duren Selatan,
Kecamatan Grogol Petamburan, Kota Jakarta Barat, Daerah Khusus Ibukota Jakarta
11470

E-Mail : yapjadi@gmail.com

Website : yapindo.co.id

© Hak cipta dilindungi oleh undang-undang

Berlaku selama 50 (lima puluh) tahun sejak ciptaan tersebut pertama kali dilakukan pengumuman.

Dilarang mengutip atau memperbanyak sebagian atau seluruh isi buku ini tanpa izin tertulis dari penerbit. Ketentuan Pidana Sanksi Pelanggaran UU No. 28 Tahun 2014 Tentang Hak Cipta.

Barang siapa dengan sengaja dan tanpa hak melakukan perbuatan sebagaimana dimaksud dalam Pasal 2 ayat (1) atau Pasal 49 ayat (1) dan ayat (2) dipidana dengan pidana penjara masing-masing paling singkat 1 (satu) bulan dan/atau denda paling sedikit Rp1.000.000,00 (satu juta rupiah), atau pidana penjara paling lama 7 (Tujuh) tahun dan/atau denda paling banyak Rp5.000.000.000,00 (lima miliar rupiah).

Barang siapa dengan sengaja menyerahkan, menyiarkan, memamerkan, mengedarkan atau menjual kepada umum suatu ciptaan atau barang hasil pelanggaran Hak Cipta atau Hak Terkait sebagaimana dimaksud pada ayat (1) dipidana dengan pidana penjara paling lama 5 (lima) tahun dan/atau denda paling banyak Rp500.000.000,00 (lima ratus juta rupiah).

KATA PENGANTAR

Puji syukur ke hadirat Tuhan Yang Maha Esa atas rahmat dan karunia-Nya, sehingga buku referensi berjudul ***Farmasi Klinis dan Pengobatan Presisi*** dapat disusun dan diselesaikan dengan baik. Kehadiran buku ini menjadi bentuk rasa syukur serta upaya untuk menghadirkan wawasan yang lebih luas mengenai perkembangan layanan kefarmasian yang terus berkembang mengikuti kebutuhan masyarakat.

Buku ini membahas berbagai konsep dan penerapan dalam farmasi klinis serta pendekatan pengobatan yang disesuaikan dengan kondisi masing-masing individu. Penyajian materi dibuat dengan bahasa yang mudah dipahami agar dapat diakses oleh berbagai kalangan pembaca tanpa batasan tertentu. Buku ini juga dipasarkan untuk masyarakat umum sebagai sarana menambah wawasan terkait perkembangan praktik pengobatan modern yang semakin adaptif dan terarah.

Harapannya, buku ini dapat memberikan manfaat dalam memperluas pemahaman serta menjadi sumber inspirasi bagi pembaca dalam melihat pentingnya ketepatan dalam pengelolaan terapi kesehatan. Semoga kehadiran buku ini dapat memberikan nilai tambah dan mendukung pemahaman yang lebih baik mengenai perkembangan dunia kesehatan masa kini.

Jakarta, Juli 2026

Tim Penyusun

DAFTAR ISI

KATA PENGANTAR	iii
DAFTAR ISI	iv
Bab 1: Landasan Farmasi Klinis dan Personalized Medicine.....	1
1.1 Konsep Dasar dan Perkembangan Farmasi Klinis.....	1
1.2 Prinsip Dasar Pelayanan Farmasi Klinis	6
1.3 Konsep Dasar dan Prinsip Personalized Medicine	12
1.4 Integrasi Personalized Medicine dalam Praktik Farmasi Klinis....	16
Bab 2: Variabilitas Respons Obat pada Individu.....	20
2.1 Pengenalan Variabilitas Respons Obat.....	20
2.2 Faktor-Faktor Genetik yang Mempengaruhi Variabilitas Respons Obat	25
2.3 Faktor-Faktor Non-Genetik dalam Variabilitas Respons Obat.....	29
2.4 Implikasi Klinis dan Pendekatan Presisi Farmasi.....	32
Bab 3: Farmakokinetik Klinis untuk Individualisasi Terapi	36
3.1 Konsep Dasar dan Parameter Farmakokinetika dalam Praktik Klinis	36
3.2 Variabilitas Farmakokinetik dan Faktor yang Memengaruhinya ..	41
3.3 Pendekatan Individualisasi Dosis Berbasis Farmakokinetik	44
3.4 Farmakokinetik Klinis sebagai Pilar Pengobatan Presisi	50
Bab 4: Farmakodinamik dan Optimasi Efek Terapi	55
4.1 Konsep Dasar Farmakodinamik dan Mekanisme Kerja	55
4.2 Variabilitas Respon Farmakodinamik Antarindividu	61
4.3 Hubungan PK/PD dalam Optimasi Terapi	67
4.4 Optimasi Efek Terapi Farmakodinamik dalam Pengobatan Presisi	71
Bab 5: Farmakogenetik dan Farmakogenomik dalam Farmasi Klinis	78
5.1 Fondasi Farmakogenetik dan Farmakogenomik.....	78

5.2 Enzim Metabolisme Obat dan Polimorfismenya.....	83
5.3 Protein Transpor Obat dan Implikasinya Farmakologis.....	89
5.4 Aplikasi Klinis Farmakogenetik dan Farmakogenomik.....	94
Bab 6: Biomarker dan Diagnostik Penunjang Terapi Presisi	98
6.1 Biomarker sebagai Pilar Pengobatan Presisi	98
6.2 Teknologi dan Platform Diagnostik Penunjang Terapi Presisi....	101
6.3 Aplikasi Biomarker dalam Pemilihan Terapi	104
6.4 Validasi dan Aspek Regulasi Biomarker.....	108
Bab 7: Therapeutic Drug Monitoring dan Precision Dosing.....	111
7.1 Definisi dan Konsep Fundamental Therapeutic Drug Monitoring	111
7.2 Metode Analitik dan Teknik Pengambilan Sampel dalam TDM	116
7.3 Model-Informed Precision Dosing dan Teknologi Biosensor	120
7.4 Aplikasi Klinis dan Tantangan Implementasi TDM dalam Praktik	125
Bab 8: Pengambilan Keputusan Klinis oleh Farmasis.....	130
8.1 Pengertian dan Pentingnya Pengambilan Keputusan Klinis.....	130
8.2 Proses Kognitif dan Tahapan Pengambilan Keputusan.....	133
8.3 Faktor-Faktor yang Mempengaruhi Pengambilan Keputusan Klinis	138
8.4 Strategi dan Alat untuk Meningkatkan Pengambilan Keputusan Klinis	142
Bab 9: Obat Pribadi pada Penyakit Hipertensi.....	147
9.1 Konsep Personalized Medicine pada Penyakit Hipertensi	147
9.2 Individualisasi Terapi Antihipertensi	151
9.3 Farmakogenomik dan Biomarker pada Hipertensi	156
9.4 Implementasi Pengobatan Presisi pada Hipertensi	159
Bab 10: Personalized Medicine pada Onkologi dan Penyakit Autoimun.....	163
10.1 Konsep Personalized Medicine dalam Onkologi dan Penyakit Autoimun.....	163

10.2 Personalized Medicine dalam Onkologi.....	167
10.3 Personalized Medicine dalam Penyakit Autoimun.....	172
10.4 Teknologi Emerging dan Tantangan Implementasi Personalized Medicine.....	176
Bab 11: Personalized Medicine pada Diabetes Mellitus	179
11.1 Konsep Dasar dan Rasionalisasi Personalized Medicine pada Diabetes Mellitus.....	179
11.2 Farmakogenomik dan Stratifikasi Genetik pada Terapi DM.....	184
11.3 Biomarker, Fenotipe, dan Pendektan Stratifikasi	190
11.4 Implementasi Personalized Medicine pada Terapi Diabetes Mellitus.....	194
Bab 12: Etika, Regulasi, Teknologi, dan Masa Depan Praktik	201
12.1 Landasan Konseptual dan Prinsip Etika dalam Pengobatan Presisi	201
12.2 Kerangka Regulasi dan Kebijakan Farmasi.....	206
12.3 Inovasi Teknologi Pendukung Pengobatan Presisi.....	212
12.4 Arah dan Tantangan Masa Depan Praktik Farmasi Klinis	216
DAFTAR PUSTAKA	222
PROFIL PENULIS.....	297

DAFTAR PUSTAKA

- AACP. (2023). Standards of practice for clinical pharmacists. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 6(10), 1156–1159. <https://doi.org/https://doi.org/10.1002/jac5.1873>
- Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., ... & TRACERx Consortium. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature*, 545(7655), 446–451. <https://doi.org/10.1038/nature22364>
- Abdul Latif El Ejel, B., Sattar, S., Fatima, S. B., Khan, H. N., Ali, H., Iftikhar, A., Sarwer, M. A., & Mushtaq, M. (2025). Digital Diabetes Management Technologies for Type 2 Diabetes: A Systematic Review of Home-Based Care Interventions. *Cureus*, 17(5), e84177. <https://doi.org/10.7759/cureus.84177>
- Abdul Malik. (2025). The Role of Therapeutic Drug Monitoring (TDM) by Clinical Pharmacists in Patients Undergoing Antibiotic Therapy : A Narrative Review. *Sarana Publikasi Farmasi Klinik Indonesia*, 1(1), 15–27.
- Abul-Husn, N. S., & Kenny, E. E. (2019). Personalized Medicine and the Power of Electronic Health Records. *Cell*, 177(1),

58–69.

<https://doi.org/https://doi.org/10.1016/j.cell.2019.02.039>

Agundez, J. A. G., & García-martín, E. (2025). Insights in pharmacogenetics and pharmacogenomics : 2023. *Frontiers in Pharmacy*, January, 1–3. <https://doi.org/10.3389/fphar.2020.595219>

Ahlqvist, E., Prasad, R. B., & Groop, L. (2020). Subtypes of Type 2 Diabetes Determined From Clinical Parameters. *Diabetes*, 69(10), 2086–2093. <https://doi.org/10.2337/dbi20-0001>

Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., Wessman, Y., Shaat, N., Spéigel, P., Mulder, H., Lindholm, E., Melander, O., Hansson, O., Malmqvist, U., Lernmark, Å., ... Groop, L. (2018). Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *The Lancet Diabetes & Endocrinology*, 6(5), 361–369. [https://doi.org/10.1016/S2213-8587\(18\)30051-2](https://doi.org/10.1016/S2213-8587(18)30051-2)

Ahmad, A., Imran, M., & Ahsan, H. (2023). Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases. *Pharmaceutics*, 15(6). <https://doi.org/10.3390/pharmaceutics15061630>

Ahmadi, M., Alizadeh, B., Ayyoubzadeh, S. M., & Abiyarghamsari, M. (2024). Predicting Pharmacokinetics of Drugs Using Artificial Intelligence Tools: A Systematic Review.

European Journal of Drug Metabolism and Pharmacokinetics, 49(3), 249–262.
<https://doi.org/10.1007/s13318-024-00883-7>

Ahmed, L., Constantinidou, A., & Chatzittofis, A. (2023). Patients' perspectives related to ethical issues and risks in precision medicine: a systematic review. *Frontiers in Medicine*, Volume 10-2023.
<https://doi.org/10.3389/fmed.2023.1215663>

Al Maruf, A., & Aziz, M. A. (2023). The potential roles of pharmacists in the clinical implementation of pharmacogenomics. *Pharmacy*, 11(6), 180.
<https://doi.org/10.3390/pharmacy11060180>

Aldoughaim, M., Alsuhebany, N., Alzahrani, M., Alqahtani, T., Alghamdi, S. S., Badreldin, H. A., & Alshaykh, H. Al. (2024). Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations. *Clinical Medicine Insights. Oncology*, 18.
<https://api.semanticscholar.org/CorpusID:274138011>

Alexandra, L., Gomes, M., Miguel, A., Costa, G., Marc, S., & Steurbaut, R. (2025). A Qualitative Study to Explore Global Trends in Clinical Pharmacy Practice. *Journal of Evaluation in Clinical Practice*, 31(07), 1–14.
<https://doi.org/https://doi.org/10.1111/jep.70104>

Alfian, S. D. (2021). Clinical pharmacists' perspective on implementation of pharmacogenomics in Indonesian hospital settings: A pilot study. *Journal of Clinical Pharmacy and*

Therapeutics, 46(3), 782–789.
<https://doi.org/10.1111/jcpt.13343>

Alharthi, M. S. (2025). How equipped are pharmacists for pharmacogenomics?: A cross-sectional study on knowledge, attitudes, and implementation practices in Saudi Arabia. *Medicine*, 104(17), e42240.
<https://doi.org/10.1097/MD.00000000000042240>

Ali, M., Suhag, A., Chowdhury, S. R., & Yeaman, S. S. (2026). Precision Medicine in Type 2 Diabetes Mellitus : Advances in Continuous Assessment , Subclassification , Personalized Therapies , and Disease Remission : A Comprehensive Review . *International Journal of Research and Scientific Innovation*, XIII(2321), 1583–1591.
<https://doi.org/10.51244/IJRSI>

Allemann, S. S., van Mil, J. W. F., Botermann, L., Berger, K., Griesse, N., & Hersberger, K. E. (2014). Pharmaceutical Care: the PCNE definition 2013. *International Journal of Clinical Pharmacy*, 36(3), 544–555. <https://doi.org/10.1007/s11096-014-9933-x>

Alqahtani, S. S., Menachery, S. J., Alshahrani, A., Albalkhi, B., Alshayban, D., & Iqbal, M. Z. (2025). Artificial intelligence in clinical pharmacy — A systematic review of current scenario and future perspectives. *Digital Health*, 11, 1–23.
<https://doi.org/10.1177/20552076251388145>

Alzahrani, F., Almutairi, N., Aloufi, A., Kattan, A., Hakeem, A., Alharbi, M., Alarawi, N., Fadil, H. A., & Habeeb, E. (2025).

- Adoption of evidence-based medicine: A comparative study of hospital and community pharmacists in Saudi Arabia. *PloS One*, 20(5), e0324620. <https://doi.org/10.1371/journal.pone.0324620>
- American Society of Health-System Pharmacists. (2022). ASHP statement on the pharmacist's role in clinical pharmacogenomics. *American Journal of Health-System Pharmacy*, 79(9), e261–e272. <https://doi.org/10.1093/ajhp/zxac061>
- Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., & Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. *Clinical Pharmacology & Therapeutics*, 103(2), 210–216. <https://doi.org/10.1002/cpt.911>
- Arbitrio, M. (2024). Pharmacogenomics: Challenges and future. *Genes*, 15(6), 714. <https://doi.org/10.3390/genes15060714>
- Armstrong, A. W., Gooderham, M., Warren, R. B., Papp, K. A., Strober, B., Thaçi, D., ... & Strober, B. (2023). Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. *Journal of the*

- American Academy of Dermatology, 88(1), 29–39.
<https://doi.org/10.1016/j.jaad.2022.07.002>
- Aronson, J. K. (2019). Concentration–effect and dose–response relations in clinical pharmacology. *British Journal of Clinical Pharmacology*, 85(11), 2504–2506.
<https://doi.org/10.1111/bcp.14054>
- Badr, Y., Kader, L. A., & Shamayleh, A. (2024). The Use of Big Data in Personalized Healthcare to Reduce Inventory Waste and Optimize Patient Treatment. *Journal of Personalized Medicine*, 14(3), 1–16.
<https://doi.org/10.3390/jpm14040383>
- Bai, B., Liu, X., & Li, H. (2026). Federated multimodal AI for precision-equitable diabetes care. *Frontiers in Digital Health*, Volume 7-2025.
<https://doi.org/10.3389/fdgth.2025.1678047>
- Banchereau, R., Hong, S., Cantarel, B., Baldwin, N., Baisch, J., Edens, M., ... & Pascual, V. (2016). Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. *Cell*, 165(3), 551–565.
<https://doi.org/10.1016/j.cell.2016.03.008>
- Banning, M. (2008). A review of clinical decision making: Models and current research. *Journal of Clinical Nursing*, 17(2), 187–195. <https://doi.org/10.1111/j.1365-2702.2006.01791.x>
- Bansal, N., Momin, S., Bansal, R., Kumar, S., Gurram, R., Ruser, L., & Yusuf, K. (2023). Pharmacokinetics of drugs : newborn

- perspective. *Pediatric Medicine*, 1–14.
<https://doi.org/10.21037/pm-22-11>
- Barbarino, J. M., Haidar, C. E., Klein, T. E., & Altman, R. B. (2023). PharmGKB summary: Very important pharmacogene information for UGT1A1. *Pharmacogenetics and Genomics*, 33(4), 81–90.
- Barker, C. I., Standing, J. F., Kelly, L. E., Thompson, A. M., & Sharland, M. (2017). Pharmacokinetic studies in children: Recommendations for practice and research. *Archives of Disease in Childhood*, 102(11), 1086–1090.
<https://doi.org/10.1136/archdischild-2016-311724>
- Barturen, G., Beretta, L., Cervera, R., Van Vollenhoven, R., & Alarcón-Riquelme, M. E. (2021). Moving towards a molecular taxonomy of autoimmune rheumatic diseases. *Nature Reviews Rheumatology*, 17(5), 251–263.
<https://doi.org/10.1038/s41584-021-00591-1>
- Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., Choudhary, P., Close, K., Danne, T., Dutta, S., Gabbay, R., Garg, S., Heverly, J., Hirsch, I. B., Kader, T., ... Phillip, M. (2023). Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. *The Lancet Diabetes & Endocrinology*, 11(1), 42–57. [https://doi.org/10.1016/S2213-8587\(22\)00319-9](https://doi.org/10.1016/S2213-8587(22)00319-9)

- Bauer, R. J. (2019). NONMEM tutorial part I: Description of commands and options, with simple examples of population analysis. *CPT: Pharmacometrics & Systems Pharmacology*, 8(8), 525–537. <https://doi.org/10.1002/psp4.12404>
- Bauer, S. R. (2014). *Applied Clinical Pharmacokinetics* (L. A. Bauer (ed.); 3rd ed.). McGraw-Hill Education. <https://accesspharmacy.mhmedical.com/book.aspx?bookid=1374>
- Beauchamp, T. L., & Childress, J. F. (2019). *Principles of Biomedical Ethics* (8 (ed.)). Oxford University Press.
- Becker, M. L., Visser, L. E., van Schaik, R. H. N., Hofman, A., Uitterlinden, A. G., & Stricker, B. H. C. (2010). Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. *Pharmacogenetics and Genomics*, 20(1), 38–44. <https://doi.org/10.1097/FPC.0b013e328333bb11>
- Beer-hammer, S., & Liebscher, I. (2024). G Protein-Coupled Receptors in Cell Signaling Transduction. *International Journal of Molecular Sciences*, 25(1), 1–2. <https://doi.org/10.3390/ijms25010291>
- Bereda, G. (2023). Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction and their Implication in Clinical Management. 13(1000539), 1–6. <https://doi.org/10.35248/2161-0495.23.13.539>
- Berezowska, M., Hayden, I. S., Brandon, A. M., Zats, A., Patel, M., Barnett, S., Ogungbenro, K., Veal, G. J., Taylor, A., &

- Suthar, J. (2025). Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. *British Journal of Clinical Pharmacology*, 91(4), 1064–1079. <https://doi.org/10.1111/bcp.16335>
- Bhatt, S., Bhatt, D. L., & Nestler, E. J. (2020). Molecular mechanisms of opioid tolerance: Implications for clinical practice. *Trends in Pharmacological Sciences*, 41(4), 265–278. <https://doi.org/10.1016/j.tips.2020.01.006>
- Bingham, J. M., Michaud, V., Turgeon, J., & Axon, D. R. (2020). Effectiveness of an advanced clinical decision support system on clinical decision-making skills in a call center medication therapy management pharmacy setting: A pilot study. *Pharmacy*, 8(4), 228. <https://doi.org/10.3390/pharmacy8040228>
- Bonate, P. L. (2011). *Pharmacokinetic-pharmacodynamic modeling and simulation* (2nd ed.). Springer.
- Borrego-Ruiz, A., & Borrego, J. J. (2025). Pharmacogenomic and pharmacomicrobiomic aspects of drugs of abuse. *Genes*, 16(4), 403. <https://doi.org/10.3390/genes16040403>
- Bououda, M., Uster, D. W., & Wicha, S. G. (2025). Model-informed precision dosing: Conceptual framework for therapeutic drug monitoring integrating machine learning and artificial intelligence within population health informatics. *Pharmaceutics*, 17(1), Article 12941472. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12941472/>

- Bremer, S., Rootwelt, H., Bergan, S., Svarstad, E., Reisæter, A. V., & Midtvedt, K. (2017). CYP3A5 genotype and tacrolimus pharmacokinetics in renal transplant recipients. *Therapeutic Drug Monitoring*, 39(2), 131–136. <https://doi.org/10.1097/FTD.0000000000000372>
- Calinski, D. M., Hoefer, C., & Kisor, D. (2021). An interprofessional education experience to promote the role of the pharmacist in precision medicine. *Currents in Pharmacy Teaching and Learning*, 13(10), 1370–1375. <https://doi.org/10.1016/j.cptl.2021.07.017>
- Campàs, M., de la Escosura-Muñiz, A., Sosa, J. A. F., & Merkoçi, A. (2019). Micro and nanotechnologies for the detection of food-borne pathogens: A critical review. *Analytica Chimica Acta*, 1048, 1–18. <https://doi.org/10.1016/j.aca.2018.10.026>
- Carter, B. L. (2016). Evolution of Clinical Pharmacy in the USA and Future Directions for Patient Care. *Drugs & Aging*, 33(3), 169–177. <https://doi.org/10.1007/s40266-016-0349-2>
- Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002). Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. *Blood*, 99(3), 754–758. <https://doi.org/10.1182/blood.v99.3.754>
- Cassataro, G., Geraci, G., Giusti, M. A., Maida, C., Maggio, V., Rizzo, M., & Mattina, A. (2026). The Cardiovascular Burden of Diabetes: Risk Factors, Clinical Phenotypes, and

- Personalized Cardiometabolic Management. *Journal of Clinical Medicine*. <https://doi.org/10.3390/jcm15062358>
- Caudle, K. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M., Relling, M. V., & Klein, T. E. (2021). Evidence and resources to implement pharmacogenomics knowledge for precision medicine. *American Journal of Health-System Pharmacy*, 78(1), e19–e26. <https://doi.org/10.1093/ajhp/zxaa315>
- Caudle, K. E., Keeling, N. J., Klein, T. E., Whirl-Carrillo, M., Pratt, V. M., & Hoffman, J. M. (2018). Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. *Pharmacogenomics*, 19(10), 847–860. <https://doi.org/10.2217/pgs-2018-0028>
- Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S., Lee, M. T. M., Klein, T. E., & Callaghan, J. T. (2014). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. *Clinical Pharmacology & Therapeutics*, 96(5), 542–548. <https://doi.org/10.1038/clpt.2014.159>
- Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., & Relling, M. V. (2020). Standardizing CYP2D6 genotype to phenotype translation: Consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics

- Working Group. *Clinical and Translational Science*, 13(1), 116–124. <https://doi.org/10.1111/cts.12692>
- Caudle, K. E., Whirl-Carrillo, M., Gammal, R. S., Klein, T. E., & Relling, M. V. (2025). Advancing clinical pharmacogenomics worldwide through the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Clinical Pharmacology & Therapeutics*. <https://doi.org/10.1002/cpt.70005>
- Chalasani, S. H., Syed, J., Ramesh, M., Patil, V., & Pramod Kumar, T. M. (2023). Artificial intelligence in the field of pharmacy practice: A literature review. *Exploratory Research in Clinical and Social Pharmacy*, 12, 100346. <https://doi.org/https://doi.org/10.1016/j.rcsop.2023.100346>
- Chandan, T. R., Patil, C., Kundgir, V. B., Chaudhari, K., Bachhav, R. L., Bhamare, M. S., Sonawane, S. K., & Mahajan, S. K. (2025). Pharmacogenomics and personalized medicine: A revolution in drug therapy. *Research Journal of Pharmacology and Pharmacodynamics*. <https://doi.org/10.52711/2321-5836.2025.00048>
- Chen, K., Li, Y., Yang, C., Xiao, P., Li, G., & Xu, Y. (2023). CYP2D6 and ADRB1 genetic polymorphisms and the selection of antihypertensive beta-receptor blockers for hypertensive patients. *American Journal of Cardiovascular Disease*, 13(4), 264–271. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10509456/>

- Chén, O. Y., & Roberts, B. (2021). Personalized Health Care and Public Health in the Digital Age. *Frontiers in Digital Health*, 3, 1–7. <https://doi.org/10.3389/fdgth.2021.595704>
- Cheng, J., Li, J., Xin, Y., & Zhang, D. (2025). Multi-phases of islet beta-cell function change in type 2 diabetes mellitus and its influencing factors. *Frontiers in Endocrinology*, Volume 16-2025. <https://doi.org/10.3389/fendo.2025.1602796>
- Chesney, J. A., Ribas, A., Long, G. V., Kirkwood, J. M., Dummer, R., Puzanov, I., ... & Sullivan, R. J. (2023). Randomized, double-blinded, placebo-controlled, global phase III trial of lifileucel versus pembrolizumab in patients with advanced melanoma after progression on a checkpoint inhibitor. *Journal of Clinical Oncology*, 41(36), 5328–5336. <https://doi.org/10.1200/JCO.23.00193>
- Christians, U., Klawitter, J., Clavijo, C. F., & Klawitter, J. (2021). Immunosuppressant drugs—Mechanisms of action. *Therapeutic Drug Monitoring*, 43(1), 3–14. <https://doi.org/10.1097/FTD.0000000000000816>
- Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., Philipson, L., McElvaine, A. T., Cefalu, W. T., Rich, S. S., & Franks, P. W. (2020). Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 43(7), 1617–1635. <https://doi.org/10.2337/dci20-0022>

- Cipriano, A., Kapil, R. P., Zhou, M., Shet, M. S., Harris, S. C., Apseloff, G., & Whiteside, G. T. (2024). Evaluation of sunobinop for next-day residual effects in healthy participants. *Frontiers in Pharmacology*, Volume 15. <https://doi.org/10.3389/fphar.2024.1432902>
- Clemens, S., Eisl-Raudaschl, L., Pachmayr, J., & Rose, O. (2025). Community Pharmacist Prescribing: Roles and Competencies-A Systematic Review and Implications. *Pharmacy* (Basel, Switzerland), 13(6). <https://doi.org/10.3390/pharmacy13060157>
- Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine*, 372(9), 793–795. <https://doi.org/10.1056/NEJMp1500523>
- Collins, F. S., Green, E. D., Guttmacher, A. E., & Guyer, M. S. (2003). A vision for the future of genomics research. *Nature*, 422(6934), 835–847. <https://doi.org/10.1038/nature01626>
- Coumau, A., Coumau, C., & Csajka, C. (2025). Implementing pharmacogenetic testing in community pharmacy practice: a scoping review. *Frontiers in Pharmacology*, 16, 1659875. <https://doi.org/10.3389/fphar.2025.1659875>
- Cremers, S., Guha, N., & Shine, B. (2020). The application of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to the therapeutic drug monitoring of immunosuppressant drugs. *Bioanalysis*, 12(9), 577–581. <https://doi.org/10.4155/bio-2020-0007>

- Cristina-elena, Marineci, C., Andrei, V., & Chirit, C. (2026). Drug – Drug and Drug – Disease Interactions Across Antidiabetic Drug Classes : A Narrative Review and Practical Recommendations. 1–50.
- Croft, A. P., Campos, J., Jansen, K., Turner, J. D., Marshall, J., Attar, M., ... & Buckley, C. D. (2019). Distinct fibroblast subsets drive inflammation and damage in arthritis. *Nature*, 570(7760), 246–251. <https://doi.org/10.1038/s41586-019-1263-7>
- Darwich, A. S., Ogungbenro, K., Vinks, A. A., Powell, J. R., Reny, J. L., Marcellin, F., ... & Rostami-Hodjegan, A. (2017). Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. *Clinical Pharmacology & Therapeutics*, 101(5), 646–656. <https://doi.org/10.1002/cpt.659>
- Darwich, A. S., Polasek, T. M., Aronson, J. K., Ogungbenro, K., Wright, D. F. B., Achour, B., Reny, J.-L., Daali, Y., Eiermann, B., Cook, J., Lesko, L., McLachlan, A. J., & Rostami-Hodjegan, A. (2021). Model-informed precision dosing: Background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. *Annual Review of Pharmacology and Toxicology*, 61, 225–245. <https://doi.org/10.1146/annurev-pharmtox-033020-113257>

- Darwich, A. S., Polasek, T. M., Aronson, J. K., Ogungbenro, K., Wright, D. F. B., Achour, B., ... & Jamei, M. (2021). Model-informed precision dosing: Background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. *Annual Review of Pharmacology and Toxicology*, 61, 225–245. <https://doi.org/10.1146/annurev-pharmtox-033020-113257>
- Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., Wang, X., Walker, M., Gough, S., Hart, L. M., Zhou, K., Forgie, I., Ruetten, H., Pavo, I., Bhatnagar, P., ... Wu, H. (2023). Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. *The Lancet Diabetes & Endocrinology*, 11(1), 33–41. [https://doi.org/https://doi.org/10.1016/S2213-8587\(22\)00340-0](https://doi.org/https://doi.org/10.1016/S2213-8587(22)00340-0)
- de Boer, N. K., Rispens, T., & Ben-Horin, S. (2018). Cross-reactive monoclonal antibody measurements of anti-drug antibodies against infliximab. *Gut*, 67(10), 1919–1920. <https://doi.org/10.1136/gutjnl-2017-314808>
- Deinum, J. (2024). HT-ENDO: A multiomics-based biomarker for the diagnosis of endocrine hypertension — A pragmatic, diagnostic, randomized, outcome-based trial (ClinicalTrials.gov Identifier No. NCT06578975). U.S.

<https://clinicaltrials.gov/study/NCT06578975>

Del Valle-Moreno, P., Suarez-Casillas, P., Mejías-Trueba, M., Ciudad-Gutiérrez, P., Guisado-Gil, A. B., Gil-Navarro, M. V., & Herrera-Hidalgo, L. (2023). Model-Informed Precision Dosing Software Tools for Dosage Regimen Individualization: A Scoping Review. *Pharmaceutics*, 15(7). <https://doi.org/10.3390/pharmaceutics15071859>

Del Valle-Moreno, P., Suárez-Casillas, P., Mejías-Trueba, M., Ciudad-Gutierrez, P., Guisado-Gil, A. B., Gil-Navarro, M. V., & Herrera-Hidalgo, L. (2023). Model-informed precision dosing software tools for dosage regimen individualization: A scoping review. *Pharmaceutics*, 15(7), Article 1859. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10386689/>

Delahaye, L., Verheggen, M. M. E. M., Stove, C. P., & Stove, V. (2019). Should we use dried blood spots in the context of home-based therapeutic drug monitoring? *Trends in Analytical Chemistry*, 113, 188–196. <https://doi.org/10.1016/j.trac.2019.02.003>

Deng, Z.-J., Gui, L., Chen, J., Peng, S.-S., Ding, Y.-F., & Wei, A.-H. (2023). Clinical, economic and humanistic outcomes of medication therapy management services: A systematic review and meta-analysis. *Frontiers in Pharmacology*, Volume 14(02). <https://doi.org/10.3389/fphar.2023.1143444>

Denny, J. C., Rutter, J. L., Goldstein, D. B., Philippakis, A., Smoller, J. W., Jenkins, G., & Dishman, E. (2019). The "All of Us"

- Research Program. *New England Journal of Medicine*, 381(7), 668–676. <https://doi.org/10.1056/NEJMSr1809937>
- Deprez, S., Verbeke, F., Dhondt, A., Stove, C., & Stove, V. (2020). Development and validation of a dried blood spot method for the simultaneous quantification of total and free plasma concentrations of voriconazole, its N-oxide metabolite, and posaconazole. *Analytical and Bioanalytical Chemistry*, 412(1), 229–243. <https://doi.org/10.1007/s00380-019-03512-6>
- Desta, Z., Gammal, R. S., Gong, L., Whirl-Carrillo, M., Gaur, A. H., Sukasem, C., Hockings, J., Myers, A., Swart, M., Tyndale, R. F., Masimirembwa, C., Iwuchukwu, O. F., Chirwa, S., Lennard, M., Gaedigk, A., & Klein, T. E. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. *Clinical Pharmacology & Therapeutics*, 106(4), 726–733. <https://doi.org/10.1002/cpt.1477>
- Dewitt, B., Persson, J., & Wallin, A. (2024). Perceptions of clinical experience and scientific evidence in medical decision making: A survey of a stratified random sample of Swedish health care professionals. *Medical Decision Making*, 44(3), 335–345. <https://doi.org/10.1177/0272989X241234318>
- Dibbets, A. C., Koldewei, C., Osinga, E. P., Scheepers, H. C. J., & de Wildt, S. N. (2025). Barriers and Facilitators for Bringing Model-Informed Precision Dosing to the Patient's Bedside:

- A Systematic Review. *Clinical Pharmacology & Therapeutics*, 117(3), 633–645.
<https://doi.org/https://doi.org/10.1002/cpt.3510>
- DiPietro Mager, N., & Bright, D. (2023). Advancing Public Health through Community Pharmacy Practice. In *Pharmacy* (Basel, Switzerland) (Vol. 11, Issue 2).
<https://doi.org/10.3390/pharmacy11020056>
- Dixon, D. L., Harris, I. M., Aljadeed, R., Anderson, K. C., Aycock, A., Beavers, C., Beckman, E. J., Isaacs, D., McCoy, E., Sandler, A., Saseen, J. J., Singh, S., & Wagner, J. (2023). Overview of clinical practice guideline development, application to pharmacy practice, and roles for pharmacists. *JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY*, 6(1), 73–84.
<https://doi.org/https://doi.org/10.1002/jac5.1743>
- Domingues, C., Jarak, I., Veiga, F., & Figueiras, A. (2023). Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.
- Dominiczak, A., Delles, C., & Padmanabhan, S. (2017). Genomics and precision medicine for clinicians and scientists in hypertension. *Hypertension*, 69(5), e38–e45.
<https://doi.org/10.1161/HYPERTENSIONAHA.116.08252>
- Douma, K. F. L., Smets, E. M. A., & Allain, D. C. (2016). Non-genetic health professionals' attitude towards, knowledge of and skills in discussing and ordering genetic testing for

- hereditary cancer. *Familial Cancer*, 15(2), 341–350.
<https://doi.org/10.1007/s10689-015-9852-6>
- Downing, N. S., Shah, N. D., Aminawung, J. A., Pease, A. M., Zeitoun, J.-D., Krumholz, H. M., & Ross, J. S. (2017). Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. *JAMA*, 317(18), 1854–1863.
<https://doi.org/10.1001/jama.2017.5150>
- Dreesen, E., Baert, F., Laharie, D., Bossuyt, P., Boschetti, G., Castele, N. V., ... & Ferrante, M. (2021). Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn's disease. *Clinical Gastroenterology and Hepatology*, 19(6), 1186–1195.
<https://doi.org/10.1016/j.cgh.2020.05.048>
- Dreesen, E., Bossuyt, P., Lanitis, T., Ferrante, M., Laharie, D., Baert, F., ... & Gils, A. (2018). Simulations of dropout and cost-effectiveness of proactive infliximab therapeutic drug monitoring versus clinically-based dosing in patients with Crohn's disease. *Journal of Crohn's and Colitis*, 12(10), 1172–1181. <https://doi.org/10.1093/ecco-jcc/jjy090>
- Drugan, T., & Leucuța, D. (2024). Evaluating Novel Biomarkers for Personalized Medicine. *Diagnostics*, 14(6).
<https://doi.org/10.3390/diagnostics14060587>
- Dunnenberger, H. (Mark), Biszewski, M., Bell, G., Sereika, A., May, H., Johnson, S., & Khandekar, J. (2016). Implementation of a multidisciplinary pharmacogenomics clinic in a

- community health system. *American Journal of Health-System Pharmacy*, 73, 1956–1966. <https://doi.org/10.2146/ajhp160072>
- Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015). Preemptive clinical pharmacogenetics implementation: Current programs in five US medical centers. *Annual Review of Pharmacology and Toxicology*, 55, 89–106. <https://doi.org/10.1146/annurev-pharmtox-010814-124835>
- Dzau, V. J., & Hodgkinson, C. P. (2024). Precision hypertension. *Hypertension*, 81(4), 702–708. <https://doi.org/10.1161/HYPERTENSIONAHA.123.21710>
- El Cheikh, J., Hamed, F., Rifi, H., Dakroub, A. H., & Eid, A. H. (2025). Genetic polymorphisms influencing antihypertensive drug responses. *British Journal of Pharmacology*, 182(4), 929–950. <https://doi.org/10.1111/bph.17414>
- Elwyn, G., Durand, M. A., Song, J., Aarts, J., Barr, P. J., Berger, Z., ... Van der Weijden, T. (2017). A three-talk model for shared decision making: Multistage consultation process. *BMJ*, 359, j4891. <https://doi.org/10.1136/bmj.j4891>
- Erdmann, A., Sutter, C. R., & Bozzaro, C. (2021). Patients ' and professionals ' views related to ethical issues in precision medicine : a mixed research synthesis. *BMC Medical Ethics*, 22(16), 1–18. <https://doi.org/10.1186/s12910-021-00682-8>

- Erstad, B. L. (2022). Ethical Decision-Making in the Pharmacists' Patient Care Process. *American Journal of Pharmaceutical Education*, 86(3), 8655. <https://doi.org/https://doi.org/10.5688/ajpe8655>
- European Medicines Agency. (2022). Guideline on bioanalytical method validation (EMA/CHMP/EWP/192217/2009 Rev. 1). EMA.
- Ewan, P., Isabelle, F., R., N. P., T., M. M., E., F. S., Brian, L., M., A. F., Iwar, K., Ethel, C., Violeta, I., S., S. A., Julian, S., Jean-Jacques, R., J., H. J., M., C. P., Sian, E., Oddmund, S., Michel, P., & T., H. A. (2026). Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations. *New England Journal of Medicine*, 355(5), 467–477. <https://doi.org/10.1056/NEJMoa061759>
- Fahmi, A. M., Elewa, H., & El Jilany, I. (2022). Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. *International Journal of Clinical Pharmacy*, 44(3), 599–607. <https://doi.org/10.1007/s11096-022-01386-8>
- Fares, R., Marjorie, B., Chaballe, C., & Crunenber, R. (2025). The outcomes of pharmacist-led pharmaceutical care within community pharmacies: An overview of systematic reviews. *Research in Social and Administrative Pharmacy*, 21(5), 332–339. <https://doi.org/https://doi.org/10.1016/j.sapharm.2025.01.01>

- Fatima, A., Mansoor, M. H., Munir, A., Ali, B., & Maryam, H. (2025). Evaluation of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Biomarker of Cardiac Dysfunction Across Heart Failure Phenotypes. 17(11). <https://doi.org/10.7759/cureus.96447>
- FDA. (2019). Precision medicine. US Department of Health and Human Services. US Department of Health and Human Services. <https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine>
- Feghali, M., Venkataramanan, R., & Caritis, S. (2015). Pharmacokinetics of drugs in pregnancy. *Seminars in Perinatology*, 39(7), 512–519. <https://doi.org/10.1053/j.semperi.2015.08.003>
- Florez, J., Hirschhorn, J., & Altshuler, D. (2013). The Inherited Basis of Diabetes Mellitus: Implications for the Genetic Analysis of Complex Traits. *Annual Review of Genomics and Human Genetics*, 4, 257–291. <https://doi.org/10.1146/annurev.genom.4.070802.110436>
- Fuchs, A., Csajka, C., Thoma, Y., Buclin, T., & Widmer, N. (2021). Benchmarking therapeutic drug monitoring software: A review of available computer tools. *Clinical Pharmacokinetics*, 52(1), 9–22. <https://doi.org/10.1007/s40262-012-0020-y>
- Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T. E., & Leeder, J. S. (2017). Prediction of CYP2D6 phenotype from

- genotype across world populations. *Genetics in Medicine*, 19(1), 69–76. <https://doi.org/10.1038/gim.2016.80>
- Garcia, E. A., Newhouse, S. J., Caulfield, M. J., & Munroe, P. B. (2017). Genes and hypertension. *Current Pharmaceutical Design*, 23(4), 605–615. <https://doi.org/10.2174/1381612822666161116122926>
- Garraway, L. A., Verweij, J., & Ballman, K. V. (2013). Precision oncology: An overview. *Journal of Clinical Oncology*, 31(15), 1803–1805. <https://doi.org/10.1200/JCO.2013.49.4799>
- Garrison, L. P., Kamal-Bahl, S., & Towse, A. (2017). Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. *Value in Health*, 20(2), 213–216. <https://doi.org/https://doi.org/10.1016/j.jval.2016.12.005>
- Gastens, V., Tancredi, S., Kiszio, B., Del Giovane, C., Tsuyuki, R. T., Paradis, G., Chiolero, A., & Santschi, V. (2025). Pharmacists delivering hypertension care services: A systematic review and meta-analysis of randomized controlled trials. *Frontiers in Cardiovascular Medicine*, 12, Article 1477729. <https://doi.org/10.3389/fcvm.2025.1477729>
- Gehrke-Beck, S., Petersen, M., Herrmann, W. J., Zimmermann, N., Daub, E., Seeger, J., ... Behrend, R. (2023). Development of a project for interprofessional collaboration between medical and pharmacy students to improve medication safety in

- polypharmacy (PILLE). *GMS Journal for Medical Education*, 40(1), Doc14.
<https://doi.org/10.3205/zma001585>
- Giacon, M., & Terrazzino, S. (2025). Precision pharmacovigilance integrates genomics and real world evidence to overcome drug safety barriers. *Discover Pharmaceutical Sciences*, 1(1), 29. <https://doi.org/10.1007/s44395-025-00032-2>
- Giannopoulou, E., Katsila, T., Mitropoulou, C., Tsermpini, E., Patrinos, G. P., & Borg, J. (2019). Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow. 10(April), 1–6.
<https://doi.org/10.3389/fphar.2019.00384>
- Ginsburg, G. S., & Phillips, K. A. (2018). Precision Medicine: From Science To Value. *Health Affairs*, 37(5), 694–701.
<https://doi.org/10.1377/hlthaff.2017.1624>
- Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: From science to value. *Health Affairs*, 37(5), 694–701.
<https://doi.org/10.1377/hlthaff.2017.1624>
- Ginsburg, G. S., & Willard, H. F. (Eds.). (2019). *Genomic and precision medicine: Primary care* (3rd ed.). Academic Press.
- Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., & Meyer, U. A. (1988). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. *Nature*, 331(6155), 442–446. <https://doi.org/10.1038/331442a0>

- Gouju, J., & Legeay, S. (2023). Pharmacokinetics of obese adults: Not only an increase in weight. *Biomedicine & Pharmacotherapy*, 166, 115281. <https://doi.org/https://doi.org/10.1016/j.biopha.2023.115281>
- Graafsma, J., Murphy, R. M., Garde, E. M. W. Van De, Karapinar-c, F., Derijks, H. J., Hoge, R. H. L., Klopotoska, J. E., & Bemt, P. M. L. A. Van Den. (2024). The use of artificial intelligence to optimize medication alerts generated by clinical decision support systems : a scoping review. *Journal of the American Medical Informatics Association*, 31(07), 1411–1422.
- Green, R. C., Goddard, K. A. B., Jarvik, G. P., Amendola, L. M., Appelbaum, P. S., Berg, J. S., Bernhardt, B. A., Biesecker, L. G., Biswas, S., Blout, C. L., Bowling, K. M., Brothers, K. B., Burke, W., Caga-Anan, C. F., Chinnaiyan, A. M., Chung, W. K., Clayton, E. W., Cooper, G. M., East, K., ... Yu, J.-H. (2016). Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. *American Journal of Human Genetics*, 98(6), 1051–1066. <https://doi.org/10.1016/j.ajhg.2016.04.011>
- Grzegorowska, A., Szczerkowska-majchrzak, E., Bukowski, K., Kadac-czapska, K., Grembecka, M., & Broncel, M. (2025). Hazardous Interactions Between Food , Herbs , and Drugs in the First Stage of Biotransformation : Case Reports of

- Adverse Drug Interactions in Humans. *Molecular Science*, 26(11), 1–37.
- Guan, S., Tu, M.-J., & Yu, A.-M. (2025). Practical Pharmacokinetic-Pharmacodynamic Models in Oncology. *Pharmaceutics*, 17(11). <https://doi.org/10.3390/pharmaceutics17111452>
- Gurevich, V. V. (2022). Molecular mechanisms of GPCR signaling: A structural perspective. *International Journal of Molecular Sciences*, 22(6), 3218–3224. <https://doi.org/10.3390/ijms22063218>
- Gutierrez, M. E., Kummar, S., & Giaccone, G. (2020). Next generation oncology drug development: Opportunities and challenges. *Nature Reviews Clinical Oncology*, 6(5), 259–265.
- Haanen, J., Obeid, M., Spain, L., Carbone, F., Wang, Y., Robert, C., ... & Marabelle, A. (2022). Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*, 33(12), 1217–1238. <https://doi.org/10.1016/j.annonc.2022.10.001>
- Haber, D. A., Gray, N. S., & Bhatt, D. L. (2021). The evolving war on cancer. *Cell*, 145(1), 19–39. <https://doi.org/10.1016/j.cell.2011.01.026>
- Hadi, M. A., Neoh, C. F., Md Zain, Z., Permana, B., & Elrggal, M. E. (2021). Pharmacoeconomics and its implications for health-system pharmacy practice in developing countries: A literature review. *Journal of Applied Pharmaceutical*

- Science, 11(1), 001–010.
<https://doi.org/10.7324/JAPS.2021.110101>
- Haga, S. B. (2023). The Critical Role of Pharmacists in the Clinical Delivery of Pharmacogenetics in the U.S. *Pharmacy*, 11(5).
<https://doi.org/10.3390/pharmacy11050144>
- Han, G.-R., Goncharov, A., Eryilmaz, M., Ye, S., Palanisamy, B., Ghosh, R., Lisi, F., Rogers, E., Guzman, D., Yigci, D., Tasoglu, S., Di Carlo, D., Goda, K., McKendry, R. A., & Ozcan, A. (2025). Machine learning in point-of-care testing: innovations, challenges, and opportunities. *Nature Communications*, 16(1), 3165.
<https://doi.org/10.1038/s41467-025-58527-6>
- Hashmi, F. K., & Al-, S. K. (2016). Defining clinical pharmacy : a new paradigm. *The Pharmaceutical Journal*, 05(12), 1–5.
<https://pharmaceutical-journal.com/article/opinion/defining-clinical-pharmacy-a-new-paradigm>
- He, Z., Fu, X., Xu, Z., Alshargi, O., Rodríguez-Labrada, R., & Zhong, X.-B. (2025). Editorial: Pharmacogenomics for improving drug safety and efficacy in cancer. *Frontiers in Pharmacology*, 16, 1649258.
<https://doi.org/10.3389/fphar.2025.1649258>
- Hendrianus, H., Navasere, E., Gorog, D., Gurbel, P. A., Kim, S.-W., & Jeong, Y.-H. (2025). Precision medicine: biomarker testing for diagnosis and treatment of cardiovascular disease. *Frontiers in Medicine*, Volume 12.
<https://doi.org/10.3389/fmed.2025.1564155>

- Hepler, C. D. (2008). The Definition of Clinical Pharmacy. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 28(6), 816–817. <https://doi.org/https://doi.org/10.1592/phco.28.6.816>
- Hirata, I., Hanaoka, S., Rokutanda, R., Funakoshi, R., & Hayashi, H. (2023). Shared decision-making practices and patient values in pharmacist outpatient care for rheumatic disease: A multiple correspondence analysis. *Journal of Pharmacy & Pharmaceutical Sciences*, 26(02). <https://doi.org/10.3389/jpps.2023.11135>
- Hirata, I., Hanaoka, S., Rokutanda, R., Funakoshi, R., & Hayashi, H. (2023). Shared decision-making practices and patient values in pharmacist outpatient care for rheumatic disease: A multiple correspondence analysis. *Journal of Pharmacy & Pharmaceutical Sciences*, 26, 11135. <https://doi.org/10.3389/jpps.2023.11135>
- Hu, K., Fu, M., Huang, X., He, S., Jiao, Z., & Wang, D. (2023). Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice. *Frontiers in Pharmacology*, 14, Article 1224980. <https://doi.org/10.3389/fphar.2023.1224980>
- Huang, H., Zhao, W., Qin, N., & Duan, X. (2024). Recent Progress on Physiologically Based Pharmacokinetic (PBPK) Model: A Review Based on Bibliometrics. *Toxics*, 12(6). <https://doi.org/10.3390/toxics12060433>

- ICH, I. C. for H. of T. R. for P. for H. U. (2017). E15 Guideline: Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. ICH. <https://www.ich.org/page/efficacy-guidelines>
- Ingelman-Sundberg, M., & Pirmohamed, M. (2024). Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. *Journal of Internal Medicine*. <https://doi.org/10.1111/joim.13772>
- Inguaggiato, G., Metselaar, S., Molewijk, B., & Widdershoven, G. (2019). How moral case deliberation supports good clinical decision making. *AMA Journal of Ethics*, 21(10), E913–E919. <https://doi.org/10.1001/amajethics.2019.913>
- Isaacs, J. D., Ferraccioli, G., & Ibrahim, F. (2019). A multi-centre, randomised, open-label, stratified, superiority study comparing multi-biomarker disease activity (MBDA) score-guided with standard of care treatment in patients with moderate to severe rheumatoid arthritis. *Annals of the Rheumatic Diseases*, 78(7), 920–928. <https://doi.org/10.1136/annrheumdis-2018-214704>
- Isaic, A., Motofelea, N., Hoinoiu, T., Motofelea, A. C., Leancu, I. C., Stan, E., Gheorghe, S. R., Dutu, A. G., & Crintea, A. (2025). Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management. *Diagnostics*, 15(19). <https://doi.org/10.3390/diagnostics15192425>

ISO 15189. (2022). Medical laboratories — Requirements for quality and competence. International Organization for Standardization.

J.D Rubin. (2022). Precision medicine in clinical pharmacy: Data science competencies for the next generation of pharmacists. *American Journal of Health-System Pharmacy*, 79(9). <https://doi.org/10.1093/ajhp/zxac023>

Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., ... & TRACERx Consortium. (2017). Tracking the evolution of non–small-cell lung cancer. *New England Journal of Medicine*, 376(22), 2109–2121. <https://doi.org/10.1056/NEJMoa1616288>

Janet, W., & M., L. L. (2026). Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. *New England Journal of Medicine*, 377(1), 62–70. <https://doi.org/10.1056/NEJMra1510062>

Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S. H. I., Pacheco, J. M., ... & Ou, S. H. (2022). Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. *New England Journal of Medicine*, 387(2), 120–131. <https://doi.org/10.1056/NEJMoa2204619>

Jauquet, M., Gagnepain, P., La Porte, E., Thiebaut, A. M., Rochey, A., Legros, H., Laine, B., Berthelot, M., Roussel, V., Montaner, J., Casolla, B., Vivien, D., Lemarchand, E., Macrez, R., & Roussel, B. D. (2024). Endogenous tPA levels: A biomarker for discriminating hemorrhagic stroke

- from ischemic stroke and stroke mimics. *Annals of Clinical and Translational Neurology*, 11(11), 2877–2890.
<https://doi.org/10.1002/acn3.52197>
- Johnson, K. B., Wei, W. Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., ... & Snowdon, J. L. (2022). Precision medicine, AI, and the future of personalized health care. *Clinical and Translational Science*, 14(1), 86–93.
<https://doi.org/10.1111/cts.12884>
- Johnson, S. G., Shaw, P. B., Delate, T., Kurz, D. L., Gregg, D., Darnell, J. C., & Aquilante, C. L. (2017). Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. *Pharmacy Practice*, 15(2), 946.
<https://doi.org/10.18549/PharmPract.2017.02.946>
- Jones, D. W., Ferdinand, K. C., Taler, S. J., Whelton, P. K., Carey, R. M., Cohen, J. B., Commodore-Mensah, Y., et al. (2025). 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults. *Journal of the American College of Cardiology*, 86(18), 1567–1678.
<https://doi.org/10.1016/j.jacc.2025.04.001>
- Jørgensen, J. T. (2025). An analysis of FDA drug approvals for oncological hematological malignancies in relation to

- companion diagnostics. *Frontiers in Oncology*, 15, 1635491.
<https://doi.org/10.3389/fonc.2025.1635491>
- Kalow, W. (1962). *Pharmacogenetics: Heredity and the response to drugs*. W. B. Saunders.
- Kamepalli, S., Unnam, S., Bhanja, S., Yeduru, K. R., & Patra, P. K. (2025). Molecular mechanisms of signaling transduction pathways of drug target molecules with recent advancements and future perspectives for successful therapy: a comprehensive and exploratory review. *Beni-Suef University Journal of Basic and Applied Sciences*, 14(1), 1–51. <https://doi.org/10.1186/s43088-025-00640-y>
- Kang, J. S., & Lee, M. H. (2019). Overview of therapeutic drug monitoring. *The Korean Journal of Internal Medicine*, 24(1), 1–10. <https://doi.org/10.3904/kjim.2009.24.1.1>
- Kang, J.-S., & Lee, M.-H. (2009). Overview of Therapeutic Drug Monitoring. *The Korean Journal of Internal Medicine*, 24, 1. <https://doi.org/10.3904/kjim.2009.24.1.1>
- Kang, S. L., Kwon, J. Y., & Kim, S. M. (2024). Insights into post-marketing clinical validation of companion diagnostics with reference to the FDA, EMA, PMDA, and MFDS. *Molecular Therapy. Methods & Clinical Development*, 32(4), 101346. <https://doi.org/10.1016/j.omtm.2024.101346>
- Karabekmez, M. E. (2021). Data Ethics in Digital Health and Genomics. *The New Bioethics*, 27, 1–14. <https://doi.org/10.1080/20502877.2021.1996965>

- Kardjadj, M. (2025). Advances in Point-of-Care Infectious Disease Diagnostics: Integration of Technologies, Validation, Artificial Intelligence, and Regulatory Oversight. *Diagnostics*, 15(22).
<https://doi.org/10.3390/diagnostics15222845>
- Karkhaneh, L., Tabatabaei-Malazy, O., Bandarian, F., Mohseni, S., & Larijani, B. (2022). Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review. *Journal of Diabetes & Metabolic Disorders*, 21(1), 863–879.
<https://doi.org/10.1007/s40200-021-00908-x>
- Karlsson, M. O. (2025). In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model- Commentary on Sheiner et al. *Clinical Pharmacology and Therapeutics*, 117(6), 1516–1532.
<https://doi.org/10.1002/cpt.3663>
- Karvaly, G. B. (2024). Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy. *Pharmaceutics*, 16(6), 4–9.
- Kassogue, Y., & Fricke-Galindo, I. (2024). The impact of the human genome on interindividual variability in drug response. *Frontiers in Genetics*, 15(03).
<https://doi.org/10.3389/fgene.2024.1401604>
- KDIGO. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. 102(5).
<https://doi.org/10.1016/j.kint.2022.06.008>

- Kementerian Kesehatan Republik Indonesia. (2016). Peraturan Menteri Kesehatan Republik Indonesia Nomor 73 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Apotek. Kementerian Kesehatan Republik Indonesia.
- Khan, Y., Shanmugar, S. B., Ahmad, U. F., Mansoor, A., Gbamgbola, T. A., Farooq, W., Anene, J. I., Bedros, A. W. S., & Gulfam, M. (2024). The Implementation and Outcomes of Personalized Antihypertensive Therapy Based on Pharmacogenetic Testing: A Retrospective Study Examining Blood Pressure Control and Medication Tolerability. *Cureus*, 16(11), e74288. <https://doi.org/10.7759/cureus.74288>
- Khatri, I., van der Touw, W., Henig, I., Tran, M., & Oltersdorf, T. (2023). Personalized neoantigen cancer vaccines: current progress and future directions. *Journal for ImmunoTherapy of Cancer*, 11(12), e007419. <https://doi.org/10.1136/jitc-2023-007419>
- Ki, S. (2020). A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship
Corresponding author. *Nesthesia and Pain Medicine*, 1, 15(1), 1–6.
- Kiang, T. K. L., Ensom, M. H. H., & Chang, T. K. H. (2021). UDP-glucuronosyltransferases and clinical drug-drug interactions. *Pharmacology & Therapeutics*, 106(1), 97–132. <https://doi.org/10.1016/j.pharmthera.2004.10.013>
- Kiefer, A. F., Burgunder-Sraggen, D., & Becker, B. (2020). Mass spectrometry in clinical analysis: Progress and challenges.

- Clinical Mass Spectrometry, 16, 1–6.
<https://doi.org/10.1016/j.clinms.2020.02.001>
- Kim, K.-H., Yoo, M., Choi, M. Y., & Yoo, B. C. (2026). A Practical Roadmap for Clinical Translation of Metabolic Biomarkers: A Review. *International Journal of Molecular Sciences*, 27(4). <https://doi.org/10.3390/ijms27042030>
- Kiran, M., Xie, Y., Anjum, N., Ball, G., Pierscionek, B., & Russell, D. (2025). Machine learning and artificial intelligence in type 2 diabetes prediction: a comprehensive 33-year bibliometric and literature analysis. *Frontiers in Digital Health*, Volume 7-2025. <https://doi.org/10.3389/fdgth.2025.1557467>
- Klein, M. E., Parvez, M. M., & Shin, J.-G. (2017). Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. *Journal of Pharmaceutical Sciences*, 106(9), 2368–2379. <https://doi.org/https://doi.org/10.1016/j.xphs.2017.04.051>
- Kobrai-Abkenar, F., Salimi, S., & Pourghane, P. (2024). “Interprofessional Collaboration” among Pharmacists, Physicians, and Nurses: A Hybrid Concept Analysis. *Iranian Journal of Nursing and Midwifery Research*, 29(2), 238–244. https://doi.org/10.4103/ijnmr.ijnmr_336_22
- Kolanczyk, D. M., Merlo, J. R., Bradley, B., Flannery, A. H., Gibson, C. M., McBane, S., Murphy, J. A., Noble, J. M., Noble, M. B., Patton, H. M., Rosselli, J. L., Stone, R. H., & Thornby, K.-A. (2024). 2023 Update to the American College of Clinical Pharmacy Pharmacotherapy Didactic

- Curriculum Toolkit. *Journal of the American College of Clinical Pharmacy : JACCP*, 7(3), 255–269. <https://doi.org/10.1002/jac5.1930>
- Krauss, M., Tappe, K., Schuppert, A., Kuepfer, L., & Goerlitz, L. (2015). Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. *PLOS ONE*, 10(10), e0139423. <https://doi.org/10.1371/journal.pone.0139423>
- Lackner, M. R., Wilson, T. R., & Settleman, J. (2012). Mechanisms of acquired resistance to targeted cancer therapies. *Future Oncology*, 8, 999–1014. <https://api.semanticscholar.org/CorpusID:45946046>
- Lamb, B. M., Floyd, E. C., Barfield, R. K., Goff, J. V., Owens, T., McGee, M., Magagnoli, J., & Maxwell, W. D. (2025). Impact of direct clinical pharmacist intervention on achievement of blood pressure control at a federally qualified health center within a medically underserved area. *Journal of Primary Care & Community Health*, 16. <https://doi.org/10.1177/21501319251380623>
- Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L., & Bonham, V. L. (2018). Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice. *Health Affairs*, 37(5), 780–785. <https://doi.org/10.1377/hlthaff.2017.1595>

- Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., ... & Wolchok, J. D. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *New England Journal of Medicine*, 381(16), 1535–1546. <https://doi.org/10.1056/NEJMoa1910836>
- Larry, J. J., & L., L. D. (2026). Precision Medicine — Personalized, Problematic, and Promising. *New England Journal of Medicine*, 372(23), 2229–2234. <https://doi.org/10.1056/NEJMSb1503104>
- Launay, M., Ollier, E., Kably, B., Le Louedec, F., Thiery, G., Lanoiselée, J., & Perinel-Ragey, S. (2024). Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic Modelling. *Antibiotics (Basel, Switzerland)*, 13(8). <https://doi.org/10.3390/antibiotics13080756>
- Laura, B., A., G. J., H., P. S., & S., J. D. (2026). Assessing the Gold Standard — Lessons from the History of RCTs. *New England Journal of Medicine*, 374(22), 2175–2181. <https://doi.org/10.1056/NEJMms1604593>
- Lauschke, V. M., & Ingelman-Sundberg, M. (2026). The evolving landscape of pharmacogenomics: Current achievements and future directions. *Progress in Molecular Biology and Translational Science*. [https://doi.org/10.1016/S0031-6997\(26\)00010-4](https://doi.org/10.1016/S0031-6997(26)00010-4)

- Lauschke, V. M., Zhou, Y., & Ingelman-Sundberg, M. (2024). Pharmacogenomics beyond single common genetic variants: The way forward. *Annual Review of Pharmacology and Toxicology*, 64, 33–51. <https://doi.org/10.1146/annurev-pharmtox-051921-091209>
- Le, J., Le, H. N., Nguyen, G., Kim, R., Avedissian, S. N., Vo, C., Le, B. H., Nguyen, T. H., Nguyen, D. T., Do, D. H., Le, B., Nguyen, A.-P., Tran, T., Phung, C. K., Vu, D. A. M., Singh, K., & Sitapati, A. M. (2026). Model-Informed Precision Dosing: Conceptual Framework for Therapeutic Drug Monitoring Integrating Machine Learning and Artificial Intelligence Within Population Health Informatics. *Journal of Personalized Medicine*, 16(2). <https://doi.org/10.3390/jpm16020076>
- Le, N. N., Frater, I., Lip, S., & Padmanabhan, S. (2025). Hypertension precision medicine: The promise and pitfalls of pharmacogenomics. *Pharmacogenomics*, 26(7), 555–567. <https://doi.org/10.1080/14622416.2025.2504865>
- Lea-henry, T. N., Carland, J. E., Stocker, S. L., Sevastos, J., & Roberts, D. M. (2018). Nephropharmacology for the Clinician Clinical Pharmacokinetics in Kidney Disease Fundamental Principles. 1085–1095. <https://doi.org/10.2215/CJN.00340118>
- Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kisor, D. F., Limdi, N. A., Lee, Y. M., Scott, S. A., Hulot, J.-S., Roden, D. M., Gaedigk, A., Caudle, K. E.,

- Klein, T. E., Johnson, J. A., & Shuldiner, A. R. (2022). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. *Clinical Pharmacology & Therapeutics*, 112(5), 959–967. <https://doi.org/10.1002/cpt.2526>
- Lee, J., Beers, J. L., Geffert, R. M., & Jackson, K. D. (2024). A Review of CYP-Mediated Drug Interactions : Mechanisms and In Vitro Drug-Drug Interaction Assessment.
- Li, H., Arroyo-Currás, N., & Plaxco, K. W. (2021). Real-time in vivo drug monitoring via electrochemical aptamer-based sensors. *TrAC Trends in Analytical Chemistry*, 138, 116230. <https://doi.org/10.1016/j.trac.2021.116230>
- Li, J., Bai, J., Liu, G., Zhu, Z., & Cao, C. (2025). Exercise Intervention in Autonomic Function, Immunity, and Cardiovascular Health: A Precision Medicine Approach. *Journal of Cardiovascular Development and Disease*. <https://doi.org/10.3390/jcdd12070247>
- Li, L., Han, Z., Yang, Z., Ma, Q., Zhao, H., Wang, R., Fan, J., Zhong, L., Hu, Y., Liu, P., Zheng, Y., & Luo, Y. (2023). Circulating Inflammatory Biomarkers Level before Thrombolysis for Acute Ischemic Stroke Predicts Symptomatic Intracerebral Hemorrhage. *Aging and Disease*, 14(1), 9–13. <https://doi.org/10.14336/AD.2022.0608>
- Liang, W. S., Beaulieu-Jones, B., Smalley, S., Snyder, M., Goetz, L. H., & Schork, N. J. (2024). Emerging therapeutic drug monitoring technologies: considerations and opportunities in

- precision medicine. *Frontiers in Pharmacology*, 15, 1348112. <https://doi.org/10.3389/fphar.2024.1348112>
- Lin, M., Guo, J., Gu, Z., Tang, W., Tao, H., You, S., Jia, D., Sun, Y., & Jia, P. (2025). Machine learning and multi-omics integration: Advancing cardiovascular translational research and clinical practice. *Journal of Translational Medicine*, 23(1), Article 388. <https://doi.org/10.1186/s12967-025-06425-2>
- Lippi, G., & Ognibene, A. (2026). Perspectives on emerging challenges and training needs for the Laboratory Medicine specialist of the future. *Advances in Laboratory Medicine*, 7(1), 16–25. <https://doi.org/doi:10.1515/almed-2025-0146>
- Liu, M., Liu, J., Meng, K., Ji, Y., & Lu, L. (2025). Feasibility analysis of pharmacy practice based on the evidence-based pharmacy model in the treatment of patients with severe pneumonia. *Pakistan Journal of Medical Sciences*, 41(11), 3076–3081. <https://doi.org/10.12669/pjms.41.11.12232>
- Liu, Q., Joshi, A., Standing, J. F., & van der Graaf, P. H. (2024). Artificial Intelligence/Machine Learning: The New Frontier of Clinical Pharmacology and Precision Medicine. *Clinical Pharmacology & Therapeutics*, 115(4), 637–642. <https://doi.org/https://doi.org/10.1002/cpt.3198>
- Longstaff, H., Flamenbaum, J., Richer, E., & Egar, J. (2022). Guideline | Guidance for policy Core elements of participant consent documents for Canadian human genomics research and the National Human Genome Library : guidance for

- policy. *Canadian Medical Association Journal*, 194(44), 1500–1508. <https://doi.org/10.1503/cmaj.212063>
- Lorden, E. R., Levinson, H. M., & Bhattacharya, J. (2022). Synovial joint-on-a-chip model enables simultaneous evaluation of drug efficacy against cartilage erosion, synovial inflammation, and bone degradation. *Advanced Healthcare Materials*, 11(22), e2201234. <https://doi.org/10.1002/adhm.202201234>
- Lv, D., Wang, S., Xiao, W., Xu, J., & Jin, Y. (2026). The value of artificial intelligence combined with multimodal data analysis in tumor immunotherapy and targeted therapy. *Biochimica et Biophysica Acta. Reviews on Cancer*. <https://doi.org/10.1016/j.bbcan.2026.189562>
- Ma, R., Lin, H., & Yu, G. (2025). Unravelling Diabetes Endotypes and Associated Pathophysiology for Precision Medicine in Diabetes: Ready for Prime Time? *Diabetes Care*, 48(12), 2000–2003. <https://doi.org/10.2337/dci25-0067>
- Mage, P. L., Ferguson, B. S., Malinoff, M. D., Sims, P. C., & Plaxco, K. W. (2017). Closed-loop control of circulating drug levels in living animals. *Nature Biomedical Engineering*, 1, 0070. <https://doi.org/10.1038/s41551-017-0070>
- Mahajan, A., Spracklen, C. N., Zhang, W., Ng, M. C. Y., Petty, L. E., Kitajima, H., Yu, G. Z., Rüeger, S., Speidel, L., Kim, Y. J., Horikoshi, M., Mercader, J. M., Taliun, D., Moon, S., Kwak, S.-H., Robertson, N. R., Rayner, N. W., Loh, M., Kim, B.-J., ... Morris, A. P. (2022). Multi-ancestry genetic

study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nature Genetics*, 54(5), 560–572. <https://doi.org/10.1038/s41588-022-01058-3>

Malmivaara, A. (2021). Applicability of evidence from randomized controlled trials and systematic reviews to clinical practice: A conceptual review. *Journal of Rehabilitation Medicine*, 53, jrm00202. <https://doi.org/10.2340/16501977-2843>

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., ... & Diaz, L. A. (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab. *The Lancet Oncology*, 21(10), 1353–1365. [https://doi.org/10.1016/S1470-2045\(20\)30445-9](https://doi.org/10.1016/S1470-2045(20)30445-9)

Mark, M. (2026). Genomics, Type 2 Diabetes, and Obesity. *New England Journal of Medicine*, 363(24), 2339–2350. <https://doi.org/10.1056/NEJMr0906948>

Marques-Garcia, F. (2026). A review of pharmacogenomics in the individualization of pharmacological treatment: Present and future. *Journal of Laboratory and Precision Medicine*, 11, Article 10. <https://doi.org/10.21037/jlpm-24-36>

Marques-Garcia, F., & Martinez-Bravo, C. (2026). A review of pharmacogenomics in the individualization of pharmacological treatment: present and future. *Journal of Laboratory and Precision Medicine*, 11, 6. <https://doi.org/10.21037/jlpm-25-9>

- Martial, L. C., Aarnoutse, R. E., Schreuder, M. F., Fliegner, M., Joore, M. A., Koch, B. C., ... & Bruggemann, R. J. (2016). Implementation considerations for dried blood spot home sampling of tacrolimus in renal transplant recipients. *Therapeutic Drug Monitoring*, 38(5), 634–641. <https://doi.org/10.1097/FTD.0000000000000315>
- Martínez-Domínguez, S. J., Gargallo-Puyuelo, C. J., Alfambra, E., García-Mateo, S., Laredo, V., Duarte, A., ... & Gomollón, F. (2022). Proactive monitoring of biologic drugs in inflammatory bowel disease: Cost-effectiveness analysis. *Journal of Crohn's and Colitis*, 16(4), 549–561. <https://doi.org/10.1093/ecco-jcc/jjab164>
- Maruf, A. Al, & Aziz, M. A. (2023). The Potential Roles of Pharmacists in the Clinical Implementation of Pharmacogenomics. In *Pharmacy* (Basel, Switzerland) (Vol. 11, Issue 6). <https://doi.org/10.3390/pharmacy11060180>
- Marusyk, A., Almendro, V., & Polyak, K. (2012). Intra-tumour heterogeneity: A looking glass for cancer? *Nature Reviews Cancer*, 12(5), 323–334. <https://doi.org/10.1038/nrc3261>
- Matrana, M. R., & Campbell, B. (2020). Precision Medicine and the Institutional Review Board: Ethics and the Genome. *Ochsner*, 98–103. <https://doi.org/10.31486/toj.19.0098>
- McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., et al. (2024). 2024 ESC guidelines for the management of elevated blood pressure

- and hypertension. *European Heart Journal*, 45(38), 3912–4018. <https://doi.org/10.1093/eurheartj/ehae178>
- McPeck, C., Paul, S., Lieberenz, J., & Levy, M. (2024). Measurement of Completeness and Timeliness of Linked Electronic Health Record Pharmacy Data for Early Detection of Nonadherence to Breast Cancer Adjuvant Endocrine Therapy. *JCO Clinical Cancer Informatics*, 8(04), 1–14. <https://doi.org/10.1200/CCI.24.00115>
- Méndez Hernández, R., & Ramasco Rueda, F. (2023). Biomarkers as prognostic predictors and therapeutic guide in critically ill patients: Clinical evidence. *Journal of Personalized Medicine*, 13(2), Article 333. <https://doi.org/10.3390/jpm13020333>
- Menéndez-Arias, L. (2013). Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. *Antiviral Research*, 98(1), 93–120. <https://doi.org/https://doi.org/10.1016/j.antiviral.2013.01.007>
- Mertens, J. F., Kempen, T. G. H., Koster, E. S., Deneer, V. H. M., Bouvy, M. L., & van Gelder, T. (2024). Cognitive processes in pharmacists' clinical decision-making. *Research in Social and Administrative Pharmacy*, 20(2), 105–114. <https://doi.org/10.1016/j.sapharm.2023.10.007>
- Mertens, J. F., Koster, E. S., Deneer, V. H. M., Bouvy, M. L., & van Gelder, T. (2023). Factors influencing pharmacists' clinical decision making in pharmacy practice. *Research in Social*

and Administrative Pharmacy.

<https://www.sciencedirect.com/science/article/pii/S1551741123002735>

Michie, S., van Stralen, M. M., & West, R. (2011). The behaviour change wheel: A new method for characterising and designing behaviour change interventions. *Implementation Science*, 6, 42. <https://doi.org/10.1186/1748-5908-6-42>

Miller, D. T., Lee, K., Chung, W. K., Gordon, A. S., Herman, G. E., Klein, T. E., ... & ClinGen Secondary Findings Working Group. (2021). ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing. *Genetics in Medicine*, 23(8), 1381–1386. <https://doi.org/10.1038/s41436-021-01172-3>

Minichmayr, I. K., Dreesen, E., Centanni, M., Wang, Z., Hoffert, Y., Friberg, L. E., & Wicha, S. G. (2024). Recent advances addressing the challenges of precision dosing. *Clinical Pharmacology & Therapeutics*, 116(3), 595–609. <https://doi.org/10.1002/cpt.3365>

Minichmayr, I. K., Mizuno, T., Goswami, S., Peck, R. W., & Polasek, T. M. (2024). Recent advances addressing the challenges of precision dosing. *Clinical Pharmacology & Therapeutics*, 116(3), 527–530. <https://doi.org/10.1002/cpt.3365>

Minichmayr, I., Dreesen, E., Centanni, M., Wang, Z., Hoffert, Y., Friberg, L. E., & Wicha, S. (2024). Model-informed precision dosing: State of the art and future perspectives.

<https://doi.org/10.1016/j.addr.2024.115421>

Misra, S., Wagner, R., Ozkan, B., Schön, M., Sevilla-Gonzalez, M., Prystupa, K., Wang, C. C., Kreienkamp, R. J., Cromer, S. J., Rooney, M. R., Duan, D., Thuesen, A. C. B., Wallace, A. S., Leong, A., Deutsch, A. J., Andersen, M. K., Billings, L. K., Eckel, R. H., Sheu, W. H.-H., ... PMDI, A. (2023). Precision subclassification of type 2 diabetes: a systematic review. *Communications Medicine*, 3(1), 138. <https://doi.org/10.1038/s43856-023-00360-3>

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., ... & Fukuoka, M. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. *New England Journal of Medicine*, 361(10), 947–957. <https://doi.org/10.1056/NEJMoa0810699>

Morales Castro, D., Dresser, L., Granton, J., & Fan, E. (2023). Pharmacokinetic Alterations Associated with Critical Illness. *Clinical Pharmacokinetics*, 62(2), 209–220. <https://doi.org/10.1007/s40262-023-01213-x>

Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., ... & TULIP-2 Trial Investigators. (2020). Trial of anifrolumab in active systemic lupus erythematosus. *New England Journal of Medicine*, 382(3), 211–221. <https://doi.org/10.1056/NEJMoa1912196>

Mould, D. R., & Upton, R. N. (2013). Basic concepts in population modeling, simulation, and model-based drug development—

- Part 2: Introduction to pharmacokinetic modeling methods. CPT: Pharmacometrics & Systems Pharmacology, 2, e38. <https://doi.org/10.1038/psp.2013.14>
- Mubarak, S., & Ashraf, M. (2024). Ethics considerations for precision medicine research and genetic testing in low- and middle-income countries. *Eastern Mediterranean Health Journal*, 30(6), 455–460.
- Munzel, T. (2021). Nitrate tolerance and oxidative stress: New insights and therapeutic implications. *European Heart Journal*, 42(38), 3960–3972. <https://doi.org/10.1093/eurheartj/ehab521>
- Nazir, A., Nazir, A., Afzaal, U., Aman, S., Sadiq, S. ur R., Akah, O. Z., Jamal, M. S. W., & Hassan, S. Z. (2025). Advancements in Biomarkers for Early Detection and Risk Stratification of Cardiovascular Diseases—A Literature Review. *Health Science Reports*, 8(5), e70878. <https://doi.org/https://doi.org/10.1002/hsr2.70878>
- Need, A. C., & Goldstein, D. B. (2009). Next generation disparities in human genomics: Concerns and remedies. *Trends in Genetics*, 25(11), 489–494. <https://doi.org/10.1016/j.tig.2009.09.012>
- Neely, M. N., van Guilder, M. G., Yamada, W. M., Schumitzky, A., & Jelliffe, R. W. (2016). Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation

- package for R. Therapeutic Drug Monitoring, 34(4), 467–476. <https://doi.org/10.1097/FTD.0b013e31825c4922>
- Neely, M. N., Youn, G., Jones, B., Jelliffe, R. W., Drusano, G. L., Rodvold, K. A., & Lodise, T. P. (2021). Are vancomycin trough concentrations adequate for optimal dosing? *Antimicrobial Agents and Chemotherapy*, 58(1), 309–316. <https://doi.org/10.1128/AAC.01653-13>
- Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., ... & Alizadeh, A. A. (2020). Integrated digital error suppression for improved detection of circulating tumor DNA. *Nature Biotechnology*, 34(5), 547–555. <https://doi.org/10.1038/nbt.3520>
- Ngcobo, N. N. (2025). Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients : A Review. In *Clinical Pharmacokinetics* (Vol. 64, Issue 3). Springer International Publishing. <https://doi.org/10.1007/s40262-024-01466-0>
- Ngcobo, N. N. (2026). Optimizing Pediatric Drug Therapy: Pediatric Pharmacokinetics and Administration Routes. *Journal of Pediatric Pharmacology and Therapeutics : JPPT*, 31(2), 196–205. <https://doi.org/10.5863/JPPT-24-00144>
- Ngo, S. T., Hung, T. M., & Nguyen, M. T. (2018). Computational prediction of drug metabolism: A review. *Briefings in Bioinformatics*, 19(5), 909–919. <https://doi.org/10.1093/bib/bbx042>

- Nguyen, D. L., Nguyen, N. D., Khurana, S., Khera, V., & Pham, C. (2020). The use of fecal calprotectin, CRP, and serum TNF-alpha in predicting disease activity and therapeutic drug monitoring in IBD patients using anti-TNF therapy. *European Journal of Gastroenterology & Hepatology*, 32(2), 202–208. <https://doi.org/10.1097/MEG.0000000000001524>
- Nicholas, C., Beharry, A., Bendzsak, A. M., Bisson, K. R., Dadson, K., Dudani, S., Iafolla, M., Irshad, K., Perdrizet, K., Raskin, W., Singh, R., Tsui, D. C. C., Wang, X., Yeung, C., Cheema, P. K., & Sheffield, B. S. (2024). Point of Care Liquid Biopsy for Cancer Treatment-Early Experience from a Community Center. *Cancers*, 16(14). <https://doi.org/10.3390/cancers16142505>
- Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., ... & Plenge, R. M. (2014). Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*, 506(7488), 376–381. <https://doi.org/10.1038/nature12873>
- Onita, T., Ishihara, N., & Yano, T. (2025). PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance. In *Antibiotics* (Vol. 14, Issue 1, p. 92). <https://doi.org/10.3390/antibiotics14010092>
- Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., et al. (2018). Hypertension. *Nature Reviews Disease Primers*, 4, Article 18014. <https://doi.org/10.1038/nrdp.2018.14>

- Ory, M. G., Adepoju, O. E., Ramos, K. S., Silva, P. S., & Vollmer Dahlke, D. (2023). Health equity innovation in precision medicine: Current challenges and future directions. *Frontiers in Public Health*, Volume 11-2023. <https://doi.org/10.3389/fpubh.2023.1119736>
- Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., ... & Wu, C. J. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature*, 547(7662), 217–221. <https://doi.org/10.1038/nature22991>
- Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., ... & Jänne, P. A. (2016). Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, 34(28), 3375–3382. <https://doi.org/10.1200/JCO.2016.66.7412>
- Padmanabhan, S., & Dominiczak, A. F. (2021). Genomics of hypertension: The road to precision medicine. *Nature Reviews Cardiology*, 18(4), 235–250. <https://doi.org/10.1038/s41569-020-00466-4>
- Pan, H.-Y., Lin, C.-W., & Chen, P.-C. (2025). Effectiveness of a nationwide community pharmacist-led program promoting home blood pressure monitoring on hypertension control and self-management. *Hypertension Research*, 48. <https://doi.org/10.1038/s41440-025-02422-6>
- Pandey, S., & Yadav, P. (2025). Liquid biopsy in cancer management: Integrating diagnostics and clinical

- applications. *Practical Laboratory Medicine*, 43, e00446.
<https://doi.org/https://doi.org/10.1016/j.plabm.2024.e00446>
- Paolinelli, J. P. V., de Alencar, T., Rocha, K. S. S., Pereira, M. L., & Dos Santos Júnior, G. A. (2025). Implementation of Clinical Pharmacy Services in Primary Health Care: A Scoping Review. *Journal of Evaluation in Clinical Practice*, 31(6), 25–28. <https://doi.org/10.1111/jep.70285>
- Papamichael, K., Afif, W., Drobne, D., Dubinsky, M. C., Ferrante, M., Irving, P. M., ... & Cheifetz, A. S. (2021). Therapeutic drug monitoring of biologics in inflammatory bowel disease: Unmet needs and future perspectives. *The Lancet Gastroenterology & Hepatology*, 7(2), 171–185. [https://doi.org/10.1016/S2468-1253\(21\)00223-5](https://doi.org/10.1016/S2468-1253(21)00223-5)
- Papamichael, K., Vogelzang, E. H., Lambert, J., Wolbink, G., & Cheifetz, A. S. (2019). Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. *Expert Review of Clinical Immunology*, 15(8), 837–848. <https://doi.org/10.1080/1744666X.2019.1645002>
- Peck, R. W., Bhatt, D. L., Garg, A., Hellings, P., Lekakis, J., Mihatov, I., ... & Stoughton, R. (2019). Are we approaching a future of personalized medicines? A roundtable discussion on the impact of precision medicines on drug development, drug regulation and health care practice. *Drug Discovery Today*, 24(8), 1672–1679. <https://doi.org/10.1016/j.drudis.2019.05.030>

- Pelaccia, T., Tardif, J., Tribby, E., & Charlin, B. (2011). An analysis of clinical reasoning through a recent and comprehensive approach: The dual-process theory. *Medical Education Online*, 16(1), 5890. <https://doi.org/10.3402/meo.v16i0.5890>
- Pérez-Blanco, J. S., & Lanao, J. M. (2022). Model-informed precision dosing (MIPD). *Pharmaceutics*, 14(12), 2731. <https://doi.org/10.3390/pharmaceutics14122731>
- Pérez-Blanco, J. S., & Lanao, J. M. (2022). Model-informed precision dosing (MIPD). *Pharmaceutics*, 14(12), Article 2731. <https://doi.org/10.3390/pharmaceutics14122731>
- Personalized Medicine Coalition. (2024). PERSONALIZED The Scope & Significance of Progress in 2024. FDA. https://www.personalizedmedicinecoalition.org/wp-content/uploads/2025/04/PMC_PM_at_FDA_2024.pdf
- PHYSIC Study. (2024). The precision hypertension care study (PHYSIC) (ClinicalTrials.gov Identifier No. NCT02774460). U.S. National Library of Medicine. <https://clinicaltrials.gov/study/NCT02774460>
- Poweleit, B. S. E. A., Vinks, P. A. A., & PhD, F. ‡ §¶ T. M. (2023). Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing. *Therapeutic Drug Monitoring*, 143–150. <https://api.semanticscholar.org/CorpusID:256663807>
- Prayuni, K., Tanuwijaya, S., Handayani, H., Sari, D. K., & Pangastuti, N. (2022). Pharmacogenomics implementation in

- Indonesia: Current status, challenges, and opportunities. *Indonesian Biomedical Journal*, 14(3), 215–227. <https://doi.org/10.18585/inabj.v14i3.1824>
- precision medicine approach to hypertension: Exploring the role of genetics, epigenetics, microbiome, and artificial intelligence. *Journal of Health, Population and Nutrition*, 44(1), Article 1058. <https://doi.org/10.1186/s41043-025-01058-z>
- Qian, Y., Wu, W., Ke, C., Liu, S., Chen, J., Chen, Y., & Guo, X. (2025). Toward Precision Dosing of Lamotrigine During Pregnancy : Physiologically Based Pharmacokinetic Modeling and Simulation. 929–940. <https://doi.org/10.1002/psp4.70007>
- Raza, K., Rouse, A., & Ramanarayanan, S. (2020). Machine learning for predicting methotrexate non-adherence in early rheumatoid arthritis. *ACR Open Rheumatology*, 2(7), 382–389.
- Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., ... & KEYNOTE-024 Investigators. (2016). Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. *New England Journal of Medicine*, 375(19), 1823–1833.
- Rehm, H. L., Berg, J. S., Brooks, L. D., Bustamante, C. D., Evans, J. P., Landrum, M. J., ... & ClinGen. (2015). ClinGen — The Clinical Genome Resource. *New England Journal of Medicine*, 372(23), 2235–2242.

- Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. *Nature*, 526(7573), 343–350. <https://doi.org/10.1038/nature15817>
- Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. *Nature*, 526(7573), 343–350. <https://doi.org/10.1038/nature15817>
- Relling, M., Klein, T., Donnelly, R., Whirl-Carrillo, M., Hoffman, J., & Caudle, K. (2019). The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. *Clinical Pharmacology & Therapeutics*, 107, 171–175. <https://doi.org/10.1002/cpt.1651>
- Ren, H.-C., Zhu, X., Hao, K., & Le, S.-Y. (2025). Application of PKPD modeling in drug discovery and development. In *Frontiers in pharmacology* (Vol. 16, p. 1614689). <https://doi.org/10.3389/fphar.2025.1614689>
- Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. *Diabetologia*, 60(9), 1577–1585. <https://doi.org/10.1007/s00125-017-4342-z>
- Rendrayani, F., Alfian, S. D., Wahyudin, W., & Puspitasari, I. M. (2022). Pharmacists' Knowledge, Attitude, and Practice of Medication Therapy Management: A Systematic Review. *Healthcare*, 10(12), 1–24. <https://doi.org/10.3390/healthcare10122513>
- Rivellese, F., Nerviani, A., Goldmann, K., Giorli, A., Kinloch, A., Pitzalis, C., ... & Lewis, M. J. (2022). Synovial biopsies in

- rheumatoid arthritis: A guide for rheumatologists. *Rheumatology*, 60(8), 3553–3562.
- Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Cardoso, F. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *New England Journal of Medicine*, 377(6), 523–533.
- Roden, D. M., McLeod, H. L., Relling, M. V, Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019). Pharmacogenomics. *The Lancet*, 394(10197), 521–532. [https://doi.org/https://doi.org/10.1016/S0140-6736\(19\)31276-0](https://doi.org/https://doi.org/10.1016/S0140-6736(19)31276-0)
- Roederer, M. W., Van Riper, M., Valgus, J., Knafl, G., & McLeod, H. (2012). Knowledge, Attitudes and Education of Pharmacists Regarding Pharmacogenetic Testing. *Personalized Medicine*, 9(1), 19–27. <https://doi.org/10.2217/pme.11.87>
- Roether, A., Guimond, A. J., Stanley, C., Pesqueira, T., & Axon, D. R. (2022). A Systematic Review of Clinical Outcomes from Pharmacist Provided Medication Therapy Management (MTM) among Patients with Diabetes , Hypertension , or Dyslipidemia. *Healthcare*, 10(12), 1–14.
- Rose, C., Shearer, E., Woller, I., Foster, A., Ashenburg, N., Kim, I., & Newberry, J. (2025). Identifying High-Priority Ethical Challenges for Precision Emergency Medicine: Nominal Group Study. *JMIR Formative Research*, 9, e68371. <https://doi.org/10.2196/68371>

Roszkowski, S. C., Babalonis, S., Coe, M., Nuzzo, P. A., Lofwall, M. R., Fanucchi, L. C., & Walsh, S. L. (2024). Residual Next-Day Effects of Alprazolam on Psychomotor Performance and Simulated Driving in Healthy Normal Adults. *Experimental and Clinical Psychopharmacology*, 33, 178–188.

<https://api.semanticscholar.org/CorpusID:274056509>

Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A., & Teichmann, S. A. (2017). The Human Cell Atlas: From vision to reality. *Nature*, 550(7677), 451–453.

Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., ... & Bhavnani, S. M. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*, 77(11), 835–864.
<https://doi.org/10.1093/ajhp/zxaa036>

S, D., & R, K. (2024). A Review of the Regulatory Challenges of Personalized Medicine. *Cureus*.
<https://doi.org/10.7759/cureus.67891>

Saber-Tehrani, A. S., Harvey, M., Ha, G., Gonzalez, D., & Huang, V. (2021). Biomarkers of acute kidney injury and nephrotoxicity: Clinical implications for vancomycin

- monitoring. *Biomarkers*, 26(5), 398–409.
<https://doi.org/10.1080/1354750X.2021.1921027>
- Sadee, W., Wang, D., Hartmann, K., & Toland, A. E. (2023). Pharmacogenomics: Driving Personalized Medicine. *Pharmacological Reviews*, 75(4), 789–814.
<https://doi.org/https://doi.org/10.1124/pharmrev.122.000810>
- Sarwar, E. (2023). Social and Ethical Implications of Integrating Precision Medicine into Healthcare BT - Global Perspectives on Precision Medicine: Ethical, Social and Public Health Implications. In E. Sarwar (Ed.), *Advancing Global Bioethics*, (pp. 125–156). Springer International Publishing.
https://doi.org/10.1007/978-3-031-28593-6_6
- Satha, A. C., Neale, J. R., Subramanian, S., & Hamlin, P. J. (2021). Cost-effectiveness of proactive therapeutic drug monitoring of anti-TNF biologics in inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, 53(1), 88–99.
<https://doi.org/10.1111/apt.16125>
- Scher, J. U., Nayak, R. R., Ubeda, C., Bhatt, A., Ranasinghe, C. J., Snieckus, P., ... & Abramson, S. B. (2020). Predictors of response to methotrexate in patients with early undifferentiated arthritis: A prospective cohort study. *The Lancet Rheumatology*, 2(2), e63–e74.
- Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., ... & IMpassion130 Trial Investigators. (2020). Atezolizumab and nab-paclitaxel in advanced triple-negative

- breast cancer. *New England Journal of Medicine*, 382(22), 2108–2111. <https://doi.org/10.1056/NEJMoa1809615>
- Schuck, R. N., & Sekar, V. (2025). Use of Biomarkers in Drug Development for Regulatory Purposes. *Clinical and Translational Science*, 18(02). <https://doi.org/https://doi.org/10.1111/cts.70377>
- Schuck, R. N., & Sekar, V. (2025). Use of Biomarkers in Drug Development for Regulatory Purposes. *Clinical and Translational Science*, 18(02). <https://doi.org/https://doi.org/10.1111/cts.70377>
- Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. *Science*, 348(6230), 69–74. <https://doi.org/10.1126/science.aaa4971>
- Selvarajan, S., & Chettiar, S. (2024). Precision medicine and personalizing therapy in a new era. *Research Journal of Medical Sciences*, 18(12), 544–548. <https://makhillpublications.co/files/published-files/mak-rjms/2024/12-544-548.pdf>
- Senger, N., & Deshmukh, S. (2025). Innovative Pharmacotherapeutic Strategies for Autoimmune and Inflammatory Disorders: Advancing Precision Medicine in Disease Management. *Journal of Pharmacology and Pharmacotherapeutics*. <https://doi.org/10.1177/0976500x251398610>
- Sessa, F., Magdy, T., Sukasem, C., & Patrinos, G. P. (2023). Editorial: Brief research reports in pharmacogenetics and

- pharmacogenomics: 2022. *Frontiers in Pharmacology*, 14, Article 1172265.
<https://doi.org/10.3389/fphar.2023.1172265>
- Shaman, J. A. (2024). The Future of Pharmacogenomics : Integrating Epigenetics , Nutrigenomics , and Beyond. *Jurnal Personalize Medicine*, 14(12).
- Shargel, L., Wu-Pong, S., & Yu, A. B. C. (2022). *Applied Biopharmaceutics & Pharmacokinetics*. McGraw-Hill Education. <https://accesspharmacy.mhmedical.com>
- Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. *Science*, 348(6230), 56–61.
<https://doi.org/10.1126/science.aaa8172>
- Sheiner, L. B., & Beal, S. L. (1982). Bayesian individualization of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods. *Journal of Pharmaceutical Sciences*, 71(12), 1344–1348.
<https://doi.org/10.1002/jps.2600711209>
- Sheiner, L. B., & Ludden, T. M. (1992). Population pharmacokinetics/dynamics. *Annual Review of Pharmacology and Toxicology*, 32, 185–209.
<https://doi.org/10.1146/annurev.pa.32.040192.001153>
- Sherwin, C. M., Kiang, T. K. L., Bhatt-Mehta, V., Buss, W. F., Dorko, C., Ensom, M. H. H., ... & Patel, P. (2019). Guidance for the practical use of population pharmacokinetic modeling in pediatric patients. *Journal of Pediatric Pharmacology and*

Therapeutics, 24(5), 371–376. <https://doi.org/10.5863/1551-6776-24.5.371>

Shields, B. M., Dennis, J. M., Angwin, C. D., Warren, F., Henley, W. E., Farmer, A. J., Sattar, N., Holman, R. R., Jones, A. G., Pearson, E. R., & Hattersley, A. T. (2023). Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. *Nature Medicine*, 29(2), 376–383. <https://doi.org/10.1038/s41591-022-02120-7>

Shipkova, M., & Wieland, E. (2016). Surface display and target drug delivery: A review. *Therapeutic Drug Monitoring*, 38(1), 3–13. <https://doi.org/10.1097/FTD.0000000000000263>

Shipkova, M., Hesselink, D. A., Holt, D. W., Billaud, E. M., Wallemacq, P., Schmaldienst, S., ... & Group, I. C. (2016). Therapeutic drug monitoring of everolimus: A consensus report. *Therapeutic Drug Monitoring*, 38(2), 143–169. <https://doi.org/10.1097/FTD.0000000000000260>

Shubbar, Q., Alchakee, A., Issa, K. W., Adi, A. J., Shorbagi, A. I., & Saber-Ayad, M. (2024). From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. *Frontiers in Pharmacology*, Volume 15-2024. <https://doi.org/10.3389/fphar.2024.1326776>

Sicklick, J. K., Nishizaki, D., Miyashita, H., Okamura, R., Hahn, M. E., Nikanjam, M., Fanta, P., Piccioni, D. E., Patel, H., Eskander, R., Mckay, R., Ross, J., Lee, J. J., Lippman, S. M., Kato, S., & Kurzrock, R. (2026). Investigation of Profile-

- Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations. *Journal of Clinical Oncology*. <https://doi.org/10.1200/JCO-25-01453>
- Simpson, M. D., & Qasim, H. S. (2025). Clinical and Operational Applications of Artificial Intelligence and Machine Learning in Pharmacy: A Narrative Review of Real-World Applications. *Pharmacy*, 13(2), 1–22.
- Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2019). Integrating liquid biopsies into the management of cancer. *Nature Reviews Clinical Oncology*, 14(9), 531–548. <https://doi.org/10.1038/nrclinonc.2017.14>
- Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., ... & Jänne, P. A. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. *New England Journal of Medicine*, 384(25), 2371–2381. <https://doi.org/10.1056/NEJMoa2103695>
- Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., ... & van der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Annals of the Rheumatic Diseases*, 79(6), 685–699. <https://doi.org/10.1136/annrheumdis-2019-216655>

- Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., ... & FLAURA Investigators. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *New England Journal of Medicine*, 378(2), 113–125. <https://doi.org/10.1056/NEJMoa1713137>
- Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. *Blood Cancer Journal*, 11(4), 69. <https://doi.org/10.1038/s41408-021-00459-7>
- Stratton, T. P., & Olson, A. W. (2023). Personalizing Personalized Medicine: The Confluence of Pharmacogenomics, a Person's Medication Experience and Ethics. *Pharmacy*, 11(3). <https://doi.org/10.3390/pharmacy11030101>
- Strik, A. S., Löwenberg, M., Mould, D. R., D'Haens, G. R., & Mathôt, R. A. A. (2022). Efficacy of dashboard-guided dosing versus standard of care in patients with inflammatory bowel disease: A randomized controlled trial. *Clinical Gastroenterology and Hepatology*, 20(5), 1108–1116. <https://doi.org/10.1016/j.cgh.2021.08.043>
- Sutton, R. T., Pincock, D., Baumgart, D. C., Sadowski, D. C., Fedorak, R. N., & Kroeker, K. I. (2020). An overview of clinical decision support systems: Benefits, risks, and strategies for success. *npj Digital Medicine*, 3, 17. <https://doi.org/10.1038/s41746-020-0221-y>
- Syrowatka, A., Motala, A., Lawson, E., & Shekelle, P. G. (2024). Computerized clinical decision support to prevent

- medication errors and adverse drug events (Making Healthcare Safer IV). Agency for Healthcare Research and Quality. <https://www.ncbi.nlm.nih.gov/books/NBK600580/>
- Talotta, D., Almasri, M., Cosentino, C., Gaidano, G., & Moia, R. (2023). Liquid biopsy in hematological malignancies: current and future applications. *Frontiers in Oncology*, Volume 13-2023. <https://doi.org/10.3389/fonc.2023.1164517>
- Tanuja, G., & Rangnath, D. B. (2025). A Review On Pharmacokinetic And Pharmacodynamic. *International Journal of Current Science*, 15(2), 1–15.
- Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., Klein, T. E., Agundéz, J. A. G., & Grosser, T. (2020). Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. *Clinical Pharmacology & Therapeutics*, 108(2), 191–200. <https://doi.org/10.1002/cpt.1830>
- Thomson, A., & Thomson, B. A. (2009). Back to basics : pharmacokinetics. *Royal College of Pharmacy*, 10, 1–10.
- Tie, J., Cohen, J. D., Lahouel, K., Lo, S. N., Wang, Y., Kosmider, S., ... & DYNAMIC Investigators. (2022). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. *New England Journal of Medicine*, 386(24), 2261–2272. <https://doi.org/10.1056/NEJMoa2200075>

- Tobias, D. (2023). Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. *Nature Medicine*, 29(October), 2438–2457. <https://doi.org/10.1038/s41591-023-02502-5>
- Tomasz Tuzimski. (2020). Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the. *Molecules*, 25(4), 1–69.
- Tremmel, R., Piroh, N., & Schwab, M. (2022). From pharmacogenetics to pharmaco-omics: Milestones and future directions. *Human Genetics and Genomics Advances*, 3(2), Article 100100. <https://doi.org/10.1016/j.xhgg.2022.100100>
- Tsekhmister, Y. (2023). Effectiveness of case-based learning in medical and pharmacy education: A meta-analysis. *Electronic Journal of General Medicine*, 20(5), em515. <https://doi.org/10.29333/ejgm/13315>
- Tuccinardi, D., Masi, D., Watanabe, M., Buffi, V. Z., Domenico, F. D., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025). Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan. *Journal of Endocrinological Investigation*. <https://doi.org/10.1007/s40618-025-02700-7>
- Uatay, A., Gall, L., Irons, L., Tewari, S. G., Zhu, X. (Sue), Gibbs, M., & Kimko, H. (2024). Physiological Indirect Response Model to Omics-Powered Quantitative Systems Pharmacology Model. *Journal of Pharmaceutical Sciences*,

- 113(1), 11–21.
<https://doi.org/https://doi.org/10.1016/j.xphs.2023.10.032>
- Udler, Kim, J., Grotthuss, M. Von, Id, B. C., Id, J. C., Anderson, C. D., Boehnke, M., Laakso, M., Atzmon, G., Glaser, B., & Id, C. F. (2018). Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes : A soft clustering analysis. 1–23.
- Unwin, N., Gan, D., & Whiting, D. (2021). The IDF Diabetes Atlas: Providing evidence, raising awareness and promoting action. *Diabetes Research and Clinical Practice*, 87(1), 2–3.
<https://doi.org/10.1016/j.diabres.2009.11.006>
- van der Graaf, P. H., & Bhansali, S. (2022). Integration of machine learning into mechanistic modelling for the design of biologic therapeutics. *Current Opinion in Structural Biology*, 73, 102322. <https://doi.org/10.1016/j.sbi.2022.102322>
- van der Heijden, J. W., Vande Casteele, N., Jurraga, M., & Dijkstra, G. (2022). Practical guidance for therapeutic drug monitoring of biologicals in gastroenterology. *Alimentary Pharmacology & Therapeutics*, 55(8), 969–985.
<https://doi.org/10.1111/apt.16706>
- van der Wouden, C. H., Marck, H., Guchelaar, H.-J., Swen, J. J., & van den Hout, W. B. (2022). Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. *Frontiers in Pharmacology*, 13(22).
<https://doi.org/10.3389/fphar.2022.918493>

- Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernelle, G., Van Steen, K., ... & Gils, A. (2015). Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. *Gastroenterology*, 148(7), 1320–1329.
<https://doi.org/10.1053/j.gastro.2015.02.031>
- Vande Casteele, N., Herfarth, H., Katz, J., Falck-Ytter, Y., & Singh, S. (2019). American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. *Gastroenterology*, 153(3), 835–857.
<https://doi.org/10.1053/j.gastro.2017.07.031>
- Vande Casteele, N., Herfarth, H., Katz, J., Falck-Ytter, Y., & Singh, S. (2017). American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. *Gastroenterology*, 153(3), 835–857.e6.
<https://doi.org/10.1053/j.gastro.2017.07.031>
- Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. *Nature*, 575(7782), 299–309.
<https://doi.org/10.1038/s41586-019-1730-1>
- Verbeeck, R. K. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. *European Journal of Clinical Pharmacology*, 64(12), 1147–1161.
<https://doi.org/10.1007/s00228-008-0553-z>

- Vermeire, S., D'Heygere, F., Nakad, A., Franchimont, D., Louis, E., De Vos, M., ... & Lambrecht, G. (2019). Preference for a prefilled syringe or an auto-injector device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: A randomized crossover study. *Patient Preference and Adherence*, 12, 1193–1202. <https://doi.org/10.2147/PPA.S158809>
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., ... & Valeri, N. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science*, 359(6378), 920–926. <https://doi.org/10.1126/science.aao2774>
- Vogeser, M., & Seger, C. (2016). Validation of LC-MS/MS methods used in clinical diagnostics—Review of current efforts. *Bioanalysis*, 8(22), 2373–2396. <https://doi.org/10.4155/bio-2016-0178>
- Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A., Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod, H. L., Roden, D. M., Williams, M. S., Green, E. D., Rodriguez, L. L., Aronson, S., Cavallari, L. H., Denny, J. C., Dressler, L. G., Johnson, J. A., Klein, T. E., Leeder, J. S., ... Relling, M. V. (2018). Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. *Clinical Pharmacology and Therapeutics*, 103(5), 778–786. <https://doi.org/10.1002/cpt.1048>

- Wallen, Z. D., Tierno, M., Schnettler, E., Roos, A., Green, M., Amoah, K., Previs, R. A., Hastings, S., Pabla, S., Jensen, T. J., Caveney, B., Eisenberg, M., Sathyan, P., Ramkissoo, S. H., & Severson, E. A. (2025). RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting. *Frontiers in Genetics*, Volume 16-2025. <https://doi.org/10.3389/fgene.2025.1550706>
- Wang, C., Li, M., Huang, Y., & Xi, X. (2023). Factors influencing clinical pharmacists' integration into the clinical multidisciplinary care team. *Frontiers in Pharmacology*, 14, 1202433. <https://doi.org/10.3389/fphar.2023.1202433>
- Wanggol, A., Wiedyaningsih, C., & Setiabudi, I. (2025). Eksplorasi Faktor-Faktor Determinan Time In Therapeutic Range Pada Pasien Lanjut Usia Dengan Fibrilasi Atrium. *Majalah Farmaseutik*, 21, 102. <https://doi.org/10.22146/farmaseutik.v21i1.103532>
- Watts, S. W., Townsend, R. R., & Neubig, R. R. (2024). How New Developments in Pharmacology Receptor Theory Are Changing (Our Understanding of) Hypertension Therapy. *American Journal of Hypertension*, 37(4), 248–260. <https://doi.org/10.1093/ajh/hpad121>
- Weinstein, I. B., & Joe, A. (2008). Oncogene addiction. *Cancer Research*, 68(9), 3077–3080. <https://doi.org/10.1158/0008-5472.CAN-07-3293>

- Wetterstrand, K. A. (2023). DNA sequencing costs: Data from the NHGRI Genome Sequencing Program (GSP). National Human Genome Research Institute. <https://www.genome.gov/sequencingcosts/>
- Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *Journal of the American College of Cardiology*, 71(19), e127–e248. <https://doi.org/10.1016/j.jacc.2017.11.006>
- Wicha, S. G., Mårtson, A. G., Nielsen, E. I., Koch, B. C. P., Friberg, L. E., Alffenaar, J. W., & Minichmayr, I. K. (2021). From therapeutic drug monitoring to model-informed precision dosing for antibiotics. *Clinical Pharmacology & Therapeutics*, 109(4), 928–941. <https://doi.org/10.1002/cpt.2202>
- Wiertz, S., & Boldt, J. (2024). Ethical, Legal, and Practical Concerns Surrounding the Implementation of New Forms of Consent for Health Data Research: Qualitative Interview Study. *Journal of Medical Internet Research*, 26. <https://doi.org/https://doi.org/10.2196/52180>
- Woillard, J. B., Mourad, M., Malluche, H. H., Aljama, P., & Marquet, P. (2021). An artificial neural network outperformed Bayesian estimation and pharmacokinetic modelling for the prediction of tacrolimus AUC₀₋₁₂. *Drug*

- Metabolism and Pharmacokinetics, 41, 100419.
<https://doi.org/10.1016/j.dmpk.2021.100419>
- Wolf, S. M., Amendola, L. M., Berg, J. S., Chung, W. K., Clayton, E. W., Eng, C. M., ... & Jarvik, G. P. (2018). Navigating the research-clinical interface in genomic medicine: Analysis from the CSER Consortium. *Genetics in Medicine*, 20(5), 545–553. <https://doi.org/10.1038/gim.2017.137>
- Wollenhaupt, C., Sudhop, T., & Knoess, W. (2023). A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation. *Diagnostics* (Basel, Switzerland), 13(12).
<https://doi.org/10.3390/diagnostics13122037>
- Wolters, M., van Paassen, J. G., Minjon, L., Hempenius, M., Blokzijl, M.-R., & Blom, L. (2021). Design of a Pharmacy Curriculum on Patient Centered Communication Skills. *Pharmacy* (Basel, Switzerland), 9(1).
<https://doi.org/10.3390/pharmacy9010022>
- Wolthuis, D. F. G. J., Nijenhuis, M., Soree, B., de Boer-Veger, N. J., Buunk, A. M., Guchelaar, H.-J., Risselada, A., Rongen, G. A. P. J. M., van Schaik, R. H. N., Swen, J. J., Touw, D. J., van Westrhenen, R., Deneer, V. H. M., & Houwink, E. J. F. (2025). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas. *European*

- Journal of Human Genetics, 33(4), 413–420.
<https://doi.org/10.1038/s41431-024-01769-7>
- World Health Organization, & International Pharmaceutical Federation. (2011). Joint FIP/WHO guidelines on good pharmacy practice: Standards for quality of pharmacy services. World Health Organization.
- Wright, D. F. B., Anakin, M. G., & Duffull, S. B. (2019). Clinical decision-making: An essential skill for 21st century pharmacy practice. *Research in Social and Administrative Pharmacy*, 15(5), 600–606.
<https://doi.org/10.1016/j.sapharm.2018.08.001>
- Wu, Y., Xue, R., Luo, X., Liao, J., Zhang, Z., Deng, J., Liu, T., Li, X., Chen, Z.-S., & Yin, M. (2026). Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions. *MedComm*, 7(3), e70638.
<https://doi.org/https://doi.org/10.1002/mco2.70638>
- Xian, H. (2024). Pharmacogenomics for precision management of hypertension. *World Journal of Pharmacology and Toxicology*, 7, Article 247.
<https://www.omicsonline.org/open-access-pdfs/pharmacogenomics-for-precision-management-of-hypertension.pdf>
- Yajima, T., Hata, F., Kurokawa, S., Sawamoto, K., Yajima, A., Furuya, D., & Sato, N. (2026). Liquid Biopsy and Automated Next-Generation Sequencing: Achieving Results in 27 Hours

- Within a Community Setting. *Diagnostics*, 16(1).
<https://doi.org/10.3390/diagnostics16010037>
- Zack, M., Stupichev, D. N., Moore, A. J., Slobodchikov, I. D., Sokolov, D. G., Trifonov, I. F., & Gobbs, A. (2025). Artificial Intelligence and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine. *Mayo Clinic Proceedings. Digital Health*, 3(3), 100246.
<https://doi.org/10.1016/j.mcpdig.2025.100246>
- Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics*, 138(1), 103–141.
[https://doi.org/https://doi.org/10.1016/j.pharmthera.2012.12.007](https://doi.org/10.1016/j.pharmthera.2012.12.007)
- Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., ... & Berger, M. F. (2017). Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,945 patients. *Nature Medicine*, 23(6), 703–713. <https://doi.org/10.1038/nm.4333>
- Zhang, Blacutt, J., Lloyd, T., Mencer, M., Pratt, V., Kotha, J., Sheeran, L., & Adcock, S. (2025). Enhancing clinical research with pharmacogenomics: a practical perspective. *Bioanalysis*, 17(6), 399–411.
<https://doi.org/10.1080/17576180.2025.2481019>
- Zhang, E. (2026). Epidemiological evidence of drug metabolism gene polymorphisms and individual differences in drug

- response. *International Journal of Biology and Life Sciences*.
<https://doi.org/10.54097/86xn3z52>
- Zhang, K., Qi, Y., Wang, W., Tian, X., Wang, J., Xu, L., & Zhai, X. (2025). Future horizons in diabetes: integrating AI and personalized care. *Frontiers in Endocrinology*, Volume 16-2025. <https://doi.org/10.3389/fendo.2025.1583227>
- Zhang, Q., & Liu, T. (2025). CYP2C19 Genotype-Guided Antiplatelet Therapy in Precision Medicine for Stroke. In *JACC. Asia* (Vol. 5, Issue 11, pp. 1454–1456). <https://doi.org/10.1016/j.jacasi.2025.08.002>
- Zhang, X., Rahnavard, A., & Crandall, K. A. (2025). Machine learning enhances biomarker discovery : From multi-omics to functional genomics . 13(8), 1–14.
- Zhang, Y., Wang, Z., Wang, Y., Jin, W., Zhang, Z., Jin, L., Qian, J., & Zheng, L. (2024). CYP3A4 and CYP3A5 : the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms. 450, 1–35. <https://doi.org/10.7717/peerj.18636>
- Zhou, K., Yee, S. W., Seiser, E. L., van Leeuwen, N., Tavendale, R., Bennett, A. J., Groves, C. J., Coleman, R. L., van der Heijden, A. A., Beulens, J. W., de Keyser, C. E., Zaharenko, L., Rotroff, D. M., Out, M., Jablonski, K. A., Chen, L., Javorský, M., Židzik, J., Levin, A. M., ... Investigators, A. (2016). Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nature*

Genetics, 48(9), 1055–1059.
<https://doi.org/10.1038/ng.3632>

Zhou, K., Yee, S. W., Seiser, E. L., van Leeuwen, N., Tavendale, R., Bennett, A. J., Groves, C. J., Coleman, R. L., van der Heijden, A. A., Beulens, J. W., de Keyser, C. E., Zaharenko, L., Rotroff, D. M., Out, M., Jablonski, K. A., Chen, L., Javorský, M., Židzik, J., Levin, A. M., ... Investigators, A. (2016). Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nature Genetics*, 48(9), 1055–1059.
<https://doi.org/10.1038/ng.3632>

Zhou, Y., & Lauschke, V. M. (2022). The genetic landscape of major drug metabolizing cytochrome P450 genes—An updated analysis of population-scale sequencing data. *The Pharmacogenomics Journal*, 22(5–6), 284–293.
<https://doi.org/10.1038/s41397-022-00288-2>

Zhou, Y., Lauschke, V. M., & Zhou, Y. (2024). Expert Review of Clinical Pharmacology Next-generation sequencing in pharmacogenomics – fit for clinical decision support ? Next-generation sequencing in pharmacogenomics – fit for clinical decision. *Expert Review of Clinical Pharmacology*, 17(3), 213–224. <https://doi.org/10.1080/17512433.2024.2307418>

Buku referensi berjudul **Farmasi Klinis dan Pengobatan Presisi** menghadirkan pemahaman modern tentang bagaimana obat digunakan secara lebih tepat sesuai kondisi tubuh setiap individu. Pembahasan mengarah pada peran penting pelayanan kefarmasian dalam membantu memilih terapi yang lebih sesuai, aman, dan efektif bagi berbagai kebutuhan kesehatan.

Dengan bahasa yang mudah dipahami, buku ini menghubungkan perkembangan farmasi modern dengan pendekatan pengobatan yang semakin personal. Isinya dirancang agar dapat dinikmati oleh masyarakat luas yang ingin memahami cara kerja obat dan perkembangan dunia kesehatan masa kini.